Emagin (EMAN) 10-K 11 Mar 20 2019 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Mar. 03, 2020	Jun. 30, 2019
Document and Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Transition Report	false
Entity File Number	001-15751
Entity Registrant Name	EMAGIN CORP
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	56-1764501
Entity Address, Address Line One	700 South Drive
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	Hopewell Junction
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	12533
City Area Code	845
Local Phone Number	838-7900
Title of 12(b) Security	Common Stock, $.001 Par Value Per Share
Trading Symbol	EMAN
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 54
Entity Common Stock, Shares Outstanding		51,300,677
Documents Incorporated by Reference	The information required by Part III of this Report, to the extent not set forth herein, is incorporated herein by reference from the registrant’s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2020 , which definitive proxy statement shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.
Amendment Flag	false
Entity Central Index Key	0001046995
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 3,515	$ 3,359
Accounts receivable, net	3,966	3,186
Unbilled accounts receivable	155	224
Inventories	8,832	8,582
Prepaid expenses and other current assets	1,130	875
Total current assets	17,598	16,226
Equipment, furniture and leasehold improvements, net	8,100	8,921
Operating lease right-of-use assets	3,729
Intangibles and other assets	160	269
Total assets	29,587	25,416
Current liabilities:
Accounts payable	1,302	2,024
Accrued compensation	1,778	1,634
Revolving credit facility, net	2,891
Common stock warrant liability	23	1,497
Other accrued expenses	1,401	1,827
Deferred revenue	277	38
Operating lease liability - current	775
Other current liabilities	342	427
Total current liabilities	8,789	7,447
Finance lease liability-long term	24
Operating lease liability-long term	3,067
Total liabilities	11,880	7,447
Commitments and contingencies (Note 9)
Shareholders' equity:
Preferred stock, $.001 par value: authorized 10,000,000 shares: Series B Convertible Preferred stock, (liquidation preference of $5,659) stated value $1,000 per share, $.001 par value: 10,000 shares designated and 5,659 issued and outstanding as of December 31, 2019 and 2018.
Common stock, $.001 par value: authorized 200,000,000 shares, issued 50,250,378 shares, outstanding 50,088,312 shares as of December 31, 2019 and issued 45,323,339 shares, outstanding 45,161,273 shares as of December 31, 2018.	50	45
Additional paid-in capital	258,767	254,736
Accumulated deficit	(240,610)	(236,312)
Treasury stock, 162,066 shares as of December 31, 2019 and 2018	(500)	(500)
Total shareholders' equity	17,707	17,969
Total liabilities and shareholders' equity	$ 29,587	$ 25,416

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	50,250,378	45,323,339
Common stock, shares outstanding	50,088,312	45,161,273
Treasury stock, shares	162,066	162,066
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation preference	$ 5,659	$ 5,659
Preferred stock, stated value	$ 1,000	$ 1,000
Preferred stock, shares designated	10,000	10,000
Preferred stock, shares issued	5,659	5,659
Preferred stock, shares outstanding	5,659	5,659

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues:
Total revenues, net	$ 26,726	$ 26,235
Cost of revenues:
Impairment of Consumer Night Vision Business inventory		2,690
Total cost of revenues	19,998	22,241
Gross profit	6,728	3,994
Operating expenses:
Research and development	5,048	6,694
Selling, general and administrative	7,251	8,967
Total operating expenses	12,299	15,661
Loss from operations	(5,571)	(11,667)
Other income (expense):
Change in fair value of common stock warrant liability	1,474	2,194
Interest expense, net	(201)	(69)
Total other income	1,273	2,125
Loss before provision for income taxes	(4,298)	(9,542)
Income taxes
Net loss	$ (4,298)	$ (9,542)
Loss per share, basic	$ (0.09)	$ (0.21)
Loss per share, diluted	$ (0.09)	$ (0.21)
Weighted average number of shares outstanding:
Basic	48,132,714	44,429,114
Diluted	48,132,714	44,429,114
Product [Member]
Revenues:
Total revenues, net	$ 24,589	$ 23,322
Cost of revenues:
Cost of goods and services sold	18,775	17,797
Contract [Member]
Revenues:
Total revenues, net	2,137	2,913
Cost of revenues:
Cost of goods and services sold	$ 1,223	$ 1,754

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Total
Balance at Dec. 31, 2017		$ 35	$ 244,726	$ (226,770)	$ (500)	$ 17,491
Balance, shares at Dec. 31, 2017	5,659	35,182,589
Exercise of common stock options			98			$ 98
Exercise of common stock options, shares		99,937				99,937
Exercise of common stock warrants			46			$ 46
Exercise of common stock warrants, shares		30,000				30,000
Public offering of common shares, net of offering costs		$ 10	9,256			$ 9,266
Public offering of common shares, net of offering costs, shares		10,010,813
Stock based compensation			610			610
Net loss				(9,542)		(9,542)
Balance at Dec. 31, 2018		$ 45	254,736	(236,312)	(500)	17,969
Balance, shares at Dec. 31, 2018	5,659	45,323,339
Exercise of common stock options			9			$ 9
Exercise of common stock options, shares		12,500				12,500
Public offering of common shares, net of offering costs		$ 5	3,471			$ 3,476
Public offering of common shares, net of offering costs, shares		4,914,539
Stock based compensation			551			551
Net loss				(4,298)		(4,298)
Balance at Dec. 31, 2019		$ 50	$ 258,767	$ (240,610)	$ (500)	$ 17,707
Balance, shares at Dec. 31, 2019	5,659	50,250,378

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (4,298)	$ (9,542)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,046	1,989
Change in fair value of common stock warrant liability	(1,474)	(2,194)
Impairment of Consumer Night Vision Business inventory		1,270
Impairment of Consumer Night Vision Business tooling		76
Stock-based compensation	551	610
Amortization of operating lease right-of-use assets	538
Changes in operating assets and liabilities:
Accounts receivable	(780)	1,342
Unbilled accounts receivable	69	183
Inventories	(250)	(2,632)
Prepaid expenses and other current assets	(255)	453
Deferred revenues	239	(727)
Operating lease liabilities	(530)
Accounts payable, accrued expenses, and other current liabilities	(966)	2,793
Net cash used in operating activities	(5,110)	(6,379)
Cash flows from investing activities:
Purchase of equipment	(1,110)	(2,296)
Net cash used in investing activities	(1,110)	(2,296)
Cash flows from financing activities:
Borrowings (repayments) under revolving line of credit, net	2,891	(3,808)
Proceeds from public offering, net	3,476	12,172
Proceeds from warrant exercise, net		46
Proceeds from exercise of stock options	9	98
Net cash provided by financing activities	6,376	8,508
Net increase (decrease) in cash and cash equivalents	156	(167)
Cash and cash equivalents, beginning of period	3,359	3,526
Cash and cash equivalents, end of period	3,515	3,359
Cash paid for interest	177	106
Cash paid for income taxes

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2019
Nature of Business [Abstract]
Nature of Business	Note 1 – Nature Of Business eMagin Corporation and its wholly owned subsidiary, Virtual Vision, Inc. (the “Company”), designs, manufactures and supplies OLED-on-silicon microdisplays and virtual imaging products which utilize OLED microdisplays. The Company’s products are sold mainly in North America, Asia, and Europe.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Significant Accounting Policies [Abstract]
Significant Accounting Policies	Note 2 – Significant Accounting Policies  Basis of Presentation  The accompanying consolidated financial statements include the accounts of eMagin Corporation and its wholly owned subsidiary. All intercompany transactions have been eliminated in consolidation. The Company manages its operations on a consolidated, integrated basis in order to optimize its equipment and facilities and to effectively service its global customer base, and concludes that it operates in a single business segment.  Use of Estimates  In accordance with accounting principles generally accepted in the United States of America, management utilizes certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments related to, among others, allowance for doubtful accounts, warranty reserves, inventory reserves, stock-based compensation expense, deferred tax asset valuation allowances, litigation and other loss contingencies. Management bases its estimates and judgments on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.  Revenue and Cost Recognition  All of the Company’s revenues are earned from contracts with customers and are classified as either Product or Contract revenues. Contracts include written agreements and purchase orders, as well as arrangements that are implied by customary practices or law.  Product revenue is generated primarily from contracts to produce, ship and deliver OLED microdisplays. eMagin’s performance obligations are satisfied, control of our products is transferred, and revenue is recognized at a single point in time when control transfers to our customer for product shipped. Our customary terms are FOB our factory and control is deemed to transfer upon shipment. The Company has elected to treat shipping and other transportation costs charged to customers as fulfillment activities and are recorded in both revenue and cost of sales at the time control is transferred to the customer. As customers are invoiced at the time control transfers and the right to consideration is unconditional at that time, the Company does not maintain contract asset balances for product revenue. Additionally, the Company does not maintain contract liability balances for product revenues, as performance obligations are satisfied prior to customer payment for product. The Company offers a one-year product warranty, for replacement of product only, and does not allow returns. The Company offers industry standard payment terms that typically require payment from our customers from 30 to 60 days after title transfers.  The Company also recognizes revenues under the over time method from certain research and development (“R&D”) activities (contract revenues) under both firm fixed-price contracts and cost-type contracts. Progress and revenues from research and development activities relating to firm fixed-price contracts and cost-type contracts are generally recognized on an input method of accounting as costs are incurred. Under the input method, revenue is recognized based on efforts expended to date (e.g., the costs of resources consumed or labor hours worked, or machine hours used) relative to total efforts intended to be expended. Contract costs include all direct material, labor and subcontractor costs and an allocation of allowable indirect costs as defined by each contract, as periodically adjusted to reflect revised agreed upon rates. These rates are subject to audit by the other party. Any changes in estimate related to contract accounting are accounted for prospectively over the remaining life of the contract. Under the over time method, billings may not correlate directly to the revenue recognized. Based upon the terms of the specific contract, billings may be in excess of the revenue recognized, in which case the amounts are included in deferred revenues as a liability on the Consolidated Balance Sheets. Likewise, revenue recognized may exceed customer billings in which case the amounts are reported as unbilled receivables. Unbilled revenues are expected to be billed and collected within one year. The incidental costs related to obtaining product sales contracts are non-recoverable from customers; and accordingly, are expensed as incurred.  The Company adopted the provisions of ASC No. 606, Revenue from Contracts with Customers, and related amendments (“ASC 606”) on January 1, 2018 using the modified retrospective adoption method with the cumulative effect of initially applying the guidance recognized at the date of initial application. During 2017, the Company analyzed its revenue recognition policies under ASC 606 and then current revenue recognition policies and determined that the performance obligations, transaction price, allocation of transaction price, recognition of contract costs and timing of revenue recognition would not be materially impacted by adopting ASC 606. Accordingly, there was no modified retrospective adoption adjustment necessary as of January 1, 2018 .  Product Warranty  The Company offers a one-year product replacement warranty. The standard policy is to repair or replace the defective products. The Company accrues for estimated returns of defective products at the time revenue is recognized based on historical activity as well as for specific known product issues. The determination of these accruals requires the Company to make estimates of the frequency and extent of warranty activity and estimate future costs to replace the products under warranty. If the actual warranty activity and/or repair and replacement costs differ significantly from these estimates, adjustments to cost of revenue may be required in future periods.  The following table provides a summary of the activity related to the Company's warranty liability, included in other current liabilities, during the years ended December 31, 2019 and 2018 (in thousands):      Twelve Months Ended  December 31,  2019 2018  Beginning balance $ 423 $ 468  Warranty accruals and adjustments 58 132  Warranty claims (181) (177)  Ending balance $ 300 $ 423  Research and Development Expenses  Research and development costs are expensed as incurred.  Cash and Cash Equivalents  All highly liquid instruments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents.  Accounts Receivable  The majority of the Company’s commercial accounts receivable are due from Original Equipment Manufacturers ("OEM’s”). Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are payable in U.S. dollars, are due within 30 - 90 days and are stated at amounts due from customers net of an allowance for doubtful accounts. Any account outstanding longer than the contractual payment terms is considered past due.  Unbilled Accounts Receivable  Unbilled receivables principally represent revenues recorded under the over time method of accounting that have not been billed to customers in accordance with the contractual terms of the arrangement. We anticipate that the majority of the balance at December 31, 2019 will be collected during the 2020 fiscal year. As of December 31, 2019 and 2018 , unbilled accounts receivable was $0.2 million and $ 0.2 million, respectively.  Allowance for Doubtful Accounts  The allowance for doubtful accounts reflects an estimate of probable losses inherent in the accounts receivable balance. The allowance is determined based on a variety of factors, including the length of time receivables are past due, historical experience, the customer's current ability to pay its obligation, and the condition of the general economy and the industry as a whole. The Company will record a specific reserve for individual accounts when the Company becomes aware of a customer's inability to meet its financial obligations, deterioration in the customer's operating results or financial position, or deterioration in the customer’s credit history. If circumstances related to customers change, the Company would further adjust estimates of the recoverability of receivables. Account balances, when determined to be uncollectible, are charged against the allowance.  Inventories  Inventories are stated on a standard cost basis adjusted to approximate the lower of cost (as determined by the first-in, first-out method) or net realizable value. Cost includes materials, labor, and manufacturing overhead related to the purchase and production of inventories. The Company regularly reviews inventory quantities on hand, future purchase commitments with the Company’s suppliers, and the estimated utility of the inventory. If the Company review indicates a reduction in utility below carrying value, the inventory is reduced to a new cost basis.  Equipment, Furniture and Leasehold Improvements  Equipment, furniture and leasehold improvements are stated at cost. Depreciation on equipment is calculated using the straight-line method of depreciation over the estimated useful life ranging from three to 10 years. Amortization of leasehold improvements is calculated by using the straight-line method over the shorter of their estimated useful lives or lease terms. Expenditures for maintenance and repairs are charged to expense as incurred. The Company performs impairment tests on its long-lived assets when circumstances indicate that their carrying amounts may not be recoverable. If required, recoverability is tested by comparing the estimated future undiscounted cash flows of the asset or asset group to its carrying value. Impairment losses, if any, are recognized based on the excess of the assets' carrying amounts over their estimated fair values.  Intangible Assets - Patents  Acquired patents are recorded at purchase price as of the date acquired and amortized over the expected useful life which is generally the remaining life of the patent. Total intangible amortization expense was approximately $32 and $54 thousand for the years ended December 31, 2019 and 2018 , respectively.    Advertising  Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. There was no advertising expense for the years ended December 31, 2019 and 2018 .  Shipping and Handling Fees  The Company includes costs related to shipping and handling in cost of goods sold.  Income Taxes  The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The effect on deferred tax assets and liabilities of changes in tax rates will be recognized as income or expense in the period that the change occurs. The Company recognizes the effect of income tax positions which are more-likely-than-not of being sustained. A valuation allowance for deferred tax assets is recorded when it is more likely than not that some or all of the benefit from the deferred tax asset will not be realized. Changes in circumstances, assumptions and clarification of uncertain tax regimes may require changes to any valuation allowances associated with the Company’s deferred tax assets.  Due to the Company’s operating loss carryforwards, all tax years remain open to examination by the major taxing jurisdictions to which the Company is subject. In the event that the Company is assessed interest or penalties at some point in the future, it will be classified in the financial statements as tax expense .  For additional details regarding our accounting for income taxes, see Note 11 in the accompanying consolidated financial statements.  Net Loss per Common Share  Basic loss per share is computed using the weighted average number of common shares outstanding during the period, and excludes any dilutive effects of common stock equivalent shares such as stock options, warrants, and convertible preferred stock. Diluted loss per share is computed using the weighted average number of common shares outstanding and potentially dilutive common stock equivalent shares outstanding during the period. Common stock equivalent shares are excluded from the computation if their effect is anti-dilutive.  In accordance with Accounting Standards Codification (“ASC”) 260, entities that have issued securities other than common stock that participate in dividends with the common stock (“participating securities”) are required to apply the two-class method to compute basic EPS. The two-class method is an earnings allocation method under which EPS is calculated for each class of common stock and participating security as if all such earnings had been distributed during the period.  The Company’s Series B Convertible Preferred stock (“Preferred Stock – Series B”) is considered a participating security as the preferred stock participates in dividends with the common stock, which requires the use of the two-class method when computing basic and diluted earnings per share. The Preferred Stock – Series B is not required to absorb any net loss. Although the Company paid a one-time special dividend in 2012, the Company does not expect to pay dividends on its common or preferred stock in the near future.  For the years ended December 31, 2019 and 2018 , the Company reported a net loss and as a result, basic and diluted loss per common share are the same. Therefore, in calculating net loss per share amounts, shares underlying the potentially dilutive common stock equivalents were excluded from the calculation of diluted net income per common share because their effect was anti-dilutive.  The following is a table of the potentially dilutive common stock equivalents for the years ended December 31, 2019 and 2018 that were not included in diluted EPS as their effect would be anti-dilutive:      Twelve Months Ended  December 31,  2019 2018  Options 5,404,985 4,678,420  Warrants 19,295,773 9,055,773  Convertible preferred stock 7,545,333 7,545,333  Total potentially dilutive common stock equivalents 32,246,091 21,279,526    Comprehensive Income (loss)  Comprehensive income (loss) refers to net income (loss) and other revenue, expenses, gains and losses that, under generally accepted accounting principles, are recorded as an element of shareholders’ equity but are excluded from the calculation of net income (loss). The Company's operations did not give rise to any material items includable in comprehensive income (loss), which were not already in net income (loss) for the years ended December 31, 2019 and 2018 . Accordingly, the Company's comprehensive income (loss) is the same as its net income (loss) for the periods presented.   Fair Value of Financial Instruments  Cash, cash equivalents, accounts receivable, short-term investments and accounts payable are stated at cost, which approximates fair value due to the short-term nature of these instruments. The Asset Based Lending Facility, (“ABL Facility”) is also stated at cost, which approximates fair value because the interest rate is based on a market based rate plus a margin.  We have categorized our assets and liabilities that are valued at fair value on a recurring basis into three-level fair value hierarchy in accordance with GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows: Level 1 – Unadjusted quoted prices in active markets of identical assets or liabilities. Level 2 – Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 – Unobservable inputs for the asset or liability. The common stock warrant liability discussed in Note 12 is currently the only financial assets or liability recorded at fair value on a recurring basis, and is considered a Level 3 liability. The fair value of the common stock warrant liability is included in current liabilities on the accompanying financial statements as of December 31, 2019 , as the warrants are currently exercisable  The following table shows the reconciliation of the Level 3 warrant liability measured and recorded at fair value on a recurring basis, using significant unobservable inputs (in thousands):     Estimated Fair Value  Balance as of January 1, 2019 $ 1,497  Fair value of warrants issuance during period -  Change in fair value of warrant liability, net (1,474)  Balance as of December 31, 2019 $ 23  The fair value of the liability for common stock purchase warrants at December 31, 2019 was estimated using the Black Scholes option pricing model based on the market value of the underlying common stock at the measurement date, the five year contractual term of the warrants, risk-free interest rates of 1.56% , no expected dividends and expected volatility of the price of the underlying common stock ranging from 40.3 % to 46.4% .  Stock-based Compensation  The Company uses the fair value method of accounting for share-based compensation arrangements. The fair values of stock options are estimated at the date of grant using the Black-Scholes option valuation model. Stock-based compensation expense is reduced for estimated forfeitures and is amortized over the vesting period using the straight-line method.  Derivative Financial Instruments  The Company evaluates all financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features qualifying as embedded derivatives. For derivative financial instruments accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statement of operations. The Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.  Concentration of Credit Risk  The majority of eMagin’s products are sold throughout North America, Asia, and Europe. Sales to the Company’s recurring customers are made generally on open account while sales to occasional customers are typically made on a prepaid basis. eMagin performs periodic credit evaluations on its recurring customers and generally does not require collateral. An allowance for doubtful accounts is maintained for credit losses.  Financial instruments which potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents and short-term investments. The Company’s cash and cash equivalents are deposited with financial institutions which, at times, may exceed federally insured limits. The Company invests surplus cash in a government money market fund that consists of U.S Government obligations and repurchase agreements collateralized by U.S. Government Obligations, which is not insured. To date, the Company has not experienced any loss associated with this risk.  Concentrations  The Company purchases principally all of its silicon wafers, which are a key ingredient in its OLED production process, from two suppliers located in Taiwan and Korea.  For the year ended December 31, 2019 and 2018 , no single customer accounted for over 10% of net revenues.  Liquidity and Going Concern  The accompanying consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue to operate as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. For the year ended December 31, 2019 , the Company incurred a net loss of $4.3 million and used cash in operating activities of $5.1 million. At December 31, 2019 , the Company had cash and cash equivalents of $3.5 million, net working capital of $8.8 million, outstanding debt of $2.9 million, and outstanding borrowing availability under its ABL Facility of $1.2 million.  Due to continuing losses, the Company’s financial position, and uncertainty regarding the Company’s ability to borrow under its ABL Facility, or continue to raise funds under its ATM facility, the Company may not be able to meet its financial obligations as they become due without additional financing or sources of capital. Management is prepared to reduce expenses and raise additional capital, but there can be no assurance that the Company will be successful in sufficiently reducing expenses or raising capital to meet its operating needs.  The Company’s ABL Facility expires on December 31, 2020 and renews automatically for another year unless terminated pursuant to its terms. Although our relationship with the lender is positive, there is no assurance the lender will renew or extend this facility, or continue to make funds available during 2020 and beyond at present availability levels, or at all. Therefore, in accordance with applicable accounting guidance, and based on the Company’s current financial condition and availability of funds, there is substantial doubt about the Company’s ability to continue as a going concern through twelve months from the date these financial statements were issued.  The Company has taken actions to increase revenues and to reduce expenses and is considering financing alternatives, but there can be no assurance that the Company will be successful in sufficiently increasing revenues, reducing expenses or securing additional financing to meet its operating needs. The Company’s plans with regard to these matters include the following actions: 1) focus production and engineering resources on improving manufacturing yields and increasing production volumes, 2) a senior management Work Status Reduction , 3) reduce headcount and not replace departed employees, 4) reduce discretionary and other expenses, and 5) considering financing and/or strategic alternatives. In October 2019, senior management work status was reduced by approximately 20% under a work status r eduction program.  Based on the Company’s current projections, operational and yield improvements, and the anticipated availability of the ABL Facility, the Company estimates it will have sufficient liquidity to fund operations through the end of the fourth quarter of 2020 . However. there can be no assurance the Company’s plans will be achieved, or that the Company will be able to continue to borrow under its ABL Facility, continue to raise funds under its ATM facility, secure additional financing, and/or pursue strategic alternatives on terms acceptable to the Company, or at all.  Accounting Policy Updates  The Company adopted Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842) on January 1, 2019. The Company evaluates whether leases are classified as operating or financing based on certain assumptions that require judgment, such as the asset's fair value, the asset's estimated residual value, the interest rate implicit in the lease, and the asset's economic useful life.  At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use (“ROU”) assets upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company records lease liabilities within current or noncurrent liabilities based upon the length of time associated with the lease payments. The operating lease ROU assets includes any lease payments made and excludes lease incentives and initial direct costs incurred, if any, and are recorded as noncurrent assets. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.  Leases with an initial term of 12 months or less are not recorded on the accompanying consolidated balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.  Equipment under capital lease obligations are classified as revenue earning assets and the related depreciation is recorded on the assets. Debt related to capital lease obligations is included in the Company’s debt obligations.  Recently Adopted Accounting Standards  In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532 - Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The Company adopted the guidance on January 1, 2019, and such adoption did not have a material impact on its financial statements.  In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) and subsequently issued amendments that replaced existing lease accounting guidance. The accounting standard requires lessees to recognize a lease liability and corresponding right-of-use asset on their balance sheets. The Company adopted the guidance effective January 1, 2019. The Company elected the transition package of three practical expedients permitted under the transition guidance and elected the optional transition method that allows for a cumulative-effect adjustment in the period of adoption, without a restatement of prior periods.  As a result of the adoption, the Company adjusted its beginning balance at January 1, 2019 by recording operating lease ROU assets and liabilities through a cumulative-effect adjustment. The adoption impacted the accompanying consolidated balance sheet, but did not have an impact on the consolidated statements of operations and comprehensive loss.  The impact of the adoption of ASC 842 on the accompanying consolidated balance sheet as of January 1, 2019 was as follows (in thousands.     December 31, 2018 Adjustments Due to the Adoption of ASC 842 January 1, 2019  Right of Use Assets (1)  Operating lease - right of use asset $ — $ 4,267 $ 4,267   Operating lease liabilities  Current $ — $ 964 $ 964  Noncurrent $ — $ 3,432 $ 3,432  (1) Operating lease right-of-use assets includes deferred rent of $129 thousand  Recently Issued Accounting Standards  In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) and subsequently issued amendments. The guidance affects the Company's accounts receivable, and it requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. This new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. Based on the composition of the Company's receivables, current market conditions and historical credit loss activity, the Company does not expect the adoption of this ASU to have a significant impact on the consolidated financial statements.  In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) a guidance that adds, amends, and removes certain disclosure requirements related to fair value measurements. Among other changes, this standard requires certain additional disclosure surrounding Level 3 assets, including changes in unrealized gains or losses in other comprehensive income and certain inputs in those measurements. This new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Certain amended or eliminated disclosures in this standard may be adopted early, while certain additional disclosure requirements in this standard can be adopted on its effective date. In addition, certain changes in the standard require retrospective adoption, while other changes must be adopted prospectively. The Company is currently evaluating the impact of this guidance on the Company’s disclosures; however, the Company does not expect the adoption of this ASU to have a significant impact on the consolidated financial statements.  In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) as part of its initiative to reduce complexity in accounting standards. This standard simplify the accounting for income taxes. This new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. This standard may be adopted early, while certain additional disclosure requirements in this standard can be adopted on its effective date. In addition, certain changes in the standard require retrospective adoption, while other changes must be adopted prospectively. The Company is currently evaluating the impact of this guidance on the Company’s disclosures; however, the Company does not expect the adoption of this ASU to have a significant impact on the consolidated financial statements.

Impairment of Consumer Night Vi

Impairment of Consumer Night Vision Business Assets	12 Months Ended
	Dec. 31, 2019
Impairment of Consumer Night Vision Business Assets [Abstract]
Impairment of Consumer Night Vision Business Assets	Note 3 - Impairment of Consumer Night Vision Business Assets  During the quarter ended June 30, 2018 the Company made a decision to exit the business associated with its two consumer night vision products, BlazeSpark and BlazeTorch (the “Consumer Night Vision Business”). The Company’s decision was based on lower than anticipated sales and an assessment performed during the quarter of the anticipated level of additional engineering, marketing and financial resources necessary to modify the products for an expanded market. As a result, the Company concluded an impairment had occurred and wrote-down $2.7 million of related Consumer Night Vision Business inventory, which includes an accrual of $1.4 million of inventory purchased by a contract manufacturer in anticipation of future production, and $0.1 million of production tooling, which are reflected in cost of revenues in the accompanying Consolidated Statements of Operations. 

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2019
Revenue Recognition [Abstract]
Revenue Recognition	Note 4 – Revenue Recognition  All of the Company’s revenues are earned from contracts with customers and are classified as either Product or Contract revenues. Contracts include written agreements and purchase orders, as well as arrangements that are implied by customary practices or law.  Disaggregation of Revenue  The Company sells products directly to milita ry contractors and OEM’s and they use our displays in a diverse range of applications encompassing the military, and commercial, including medical and industrial, market sectors . Revenues are classified as either military, commercial, consumer or multiple based on management’s knowledge of the customer’s p roducts and markets served by displays or the R&D contract work. Revenues classified as Multiple are for sales to customers that incorporate the Company’s displays in products that could be used for either Military or Commercial applications. R&D activities are performed for both military customers and U.S. Government defense related agencies and consumer companies. Product and Contract revenues are disclosed on the Consolidated Statements of Operations.  Additional disaggregated revenue information for the years ended December 31, 2019 and 2018 were as follows (in thousands):      Twelve Months Ended  December 31,  2019 2018  North and South America $ 14,566 $ 13,969  Europe, Middle East, and Africa 11,112 9,157  Asia Pacific 1,048 3,109  Total $ 26,726 $ 26,235     Twelve Months Ended  December 31,  2019 2018  Military 65 % 75 %  Commercial, including industrial and medical 12 % 10 %  Consumer 4 % 6 %  Multiple 19 % 9 %  100 % 100 %  Accounts Receivable from Customers  Accounts receivable, net of allowances, associated with revenue from customers were approximately $4.0 million and $3.2 million as of December 31, 2019 and 2018 , respectively.  Contract Assets and Liabilities  Unbilled Accounts Receivables (Contract Assets) - Pursuant to the over time revenue recognition model, revenue may be recognized prior to the customer being invoiced. An unbilled accounts receivable is recorded to reflect revenue that is recognized when the proportional performance method is applied and such revenue exceeds the amount invoiced to the customer. Unbilled receivables are disclosed on the Consolidated Balance Sheet as of December 31, 2019 and 2018 .  Customer Advances and Deposits (Contract Liabilities)  The Company recognizes a contract liability when it has billed and received consideration from the customer pursuant to the terms of a contract but has not yet recognized the related revenue. These billings in excess of revenue are classified as deferred revenue on the Consolidated Statements of Operations.  Total contract assets and liabilities consisted of the following amounts (in thousands):      December 31, December 31,  2019 2018  Unbilled Receivables (contract assets) $ 155 $ 224   Deferred Revenue (contract liabilities) $ (277) $ (38)   During the years ended December 31, 2019 and 2018, the Company recognized $0.2 million and $0.7 million of revenue related to its contract liabilities that existed at December 31, 2018 and 2017 , respectively.  Remaining Performance Obligations .  The Company has elected the practical expedient, which allows disclosure of remaining performance obligations only for contracts with an original duration of greater than one year. Such remaining performance obligations primarily relate to engineering and design services. As of December 31, 2019 and 2018 , the aggregate amount of the transaction price allocated to remaining performance obligations was $1.4 million and $1.1 million. The Company expects to recognize revenue on all of its remaining performance obligations over the next 12 months.

Accounts Receivable, Net

Accounts Receivable, Net	12 Months Ended
	Dec. 31, 2019
Accounts Receivable, Net [Abstract]
Accounts Receivable, Net	Note 5 – Accounts Receivable, net  Accounts receivable consisted of the following (in thousands):     December 31, December 31,  2019 2018  Accounts receivable $ 4,105 $ 3,325  Less allowance for doubtful accounts (139) (139)  Accounts receivable, net $ 3,966 $ 3,186

Inventories, Net

Inventories, Net	12 Months Ended
	Dec. 31, 2019
Inventories, Net [Abstract]
Inventories, Net	Note 6 – Inventories, net  The components of inventories were as follows (in thousands):     December 31, December 31,  2019 2018  Raw materials $ 2,788 $ 3,701  Work in process 1,561 1,033  Finished goods 5,248 4,888  Total inventories 9,597 9,622  Less inventory reserve (765) (1,040)  Total inventories, net $ 8,832 $ 8,582

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2019
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	Note 7 – Prepaid Expenses and Other Current Assets  Prepaid expenses and other current assets consist of the following (in thousands):     December 31,  2019 2018  Vendor prepayments $ 657 $ 702  Other prepaid expenses 473 173  Total prepaid expenses and other current assets $ 1,130 $ 875

Equipment, Furniture and Leaseh

Equipment, Furniture and Leasehold Improvements	12 Months Ended
	Dec. 31, 2019
Equipment, Furniture and Leasehold Improvements [Abstract]
Equipment, Furniture and Leasehold Improvements	Note 8 – Equipment, Furniture and Leasehold Improvements Equipment, furniture and leasehold improvements consist of the following (in thousands):     December 31,  2019 2018  Computer hardware and software $ 893 $ 800  Lab and factory equipment 17,482 17,107  Furniture, fixtures and office equipment 59 48  Assets under capital leases 116 66  Construction in progress 2,668 2,114  Leasehold improvements 60 22  Total equipment, furniture and leasehold improvements 21,278 20,157  Less: accumulated depreciation (13,178) (11,236)  Equipment, furniture and leasehold improvements, net $ 8,100 $ 8,921  Depreciation expense was $1.9 million for the years ended December 31, 2019 and 2018 , respectively. Depreciation expense was $11 thousand for assets under capital leases for the year ended December 31, 2019 .

Debt _ Line of Credit

Debt / Line of Credit	12 Months Ended
	Dec. 31, 2019
Debt / Line of Credit [Abstract]
Debt / Line of Credit	Note 9 – Debt / Line of Credit    (in thousands) 2019 2018  Revolving credit facility $ 2,891 $ —  Less: unamortized debt issuance costs — —  Revolving credit facility, net $ 2,891 $ —  On December 21, 2016, the Company entered into an ABL Facility with a lender that provides for up to a maximum amount of $5 million based on a borrowing base equivalent of 85% of eligible accounts receivable plus the lesser of $2 million or 50% of eligible inventory. The interest on the ABL Facility is equal to the Prime Rate plus 3% but may not be less than 6.5% with a minimum monthly interest payment of $2 thousand. The Company is also obligated to pay the lender a monthly administrative fee of $1 thousand and an annual facility fee equal to 1% of the maximum amount borrowable under the facility. As of December 31, 2019 , the interest rate on outstanding borrowings was 7.75% . The ABL Facility renewed on December 31, 2019 and will automatically renew on December 31, 2020 for a one -year term unless written notice to terminate the agreement is provided by either party. In conjunction wit h entering into the financing, the Company incurred $0.2 million of debt issuance costs including lender and legal costs that were amortized over the original three -year term of the ABL Facility. The ABL Facility agreement contains certain lenders remedies that upon events of default, give the bank the ability to terminate the facility before the scheduled maturity date. Accordingly, the Company classifies borrowing under the ABL Facility as current liabilities on the accompanying balance sheets. The ABL Facility is secured by a lien on all receivables, property and the proceeds thereof, credit insurance policies and other insurance relating to the collateral, books, records and other general intangibles, inventory and equipment, proceeds of the collateral and accounts, instruments, chattel paper, and documents. Collections received on accounts receivable are directly used to pay down the outstanding borrowings on the credit facility. The ABL Facility contains customary representations and warranties, affirmative and negative covenants and events of default. The Company is required to maintain a minimum tangible net worth of $13 million and a minimum working capital balance of $4 million at all times. As of December 31, 2019 , the Company had unused borrowing availability of $1.2 million and were in compliance with all financial debt covenants.  For the years ended December 31, 2019 and 2018 , interest expense includes interest paid, or accrued, and amortization or write-off of debt issuance costs of approximately $82 thousand on outstanding debt.

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	Note 10 – Leases  The Company leases office and manufacturing facilities in Hopewell Junction, NY under a non-cancelable operating lease agreement. The lease for these facilities, as amended, expires in May 2024 and does not contain a renewal option. The lease agreement does not contain any residual value guarantees, or m aterial restrictive covenants.  The Company also leases an office facility for its design group in Santa Clara, California. During the fourth quarter of 2019, the Company signed a two -year extension of this lease that expires in October 2021 . The lease agreement does not contain a ny residual value guarantees, m aterial restrictive covenants or a renewal option .  The Company's operating leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. The Company used incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date.  On May 2, 2019, the Company entered into a three -year finance lease commitment for phone equipment. Finance leases are included in e quipment, furniture and leasehold improvements, net, Other current liabilities , and Finance lease liability – long term in our consolidated Balance Sheet.  Rent expense was approximately $ 1.0 million for each of the years ended December 31, 2019 and 2018.  The components of lease expense were as follows (in thousands ):     Twelve Months Ended  December 31, 2019  Finance Lease Cost:  Amortization of right-of-use assets $ 11  Interest on lease liabilities 3  Operating lease cost 986  Short-term lease cost 58  Total Lease Cost $ 1,058     Other Information  Cash paid for amounts included in the measurement lease liabilities:  Operating cash flows from operating leases $ 1,012  Financing cash flows from finance leases $ 13  Right-of-use assets obtained in exchange for new finance lease liabilities $ 50  Right-of-use assets obtained in exchange for new operating lease liabilities $ 110     December 31, 2019  Finance lease right-of-use assets $ 40  Operating lease right-of-use assets $ 3,729  Finance lease liability, current $ 16  Finance lease liability, non-current $ 24  Operating lease liabilities, current $ 775  Operating lease liabilities, non-current $ 3,067  Weighted average remaining lease terms - finance leases 2.33 years  Weighted average remaining lease terms - operating leases 4.42 years  Weighted average discount rate - finance leases 10.91%  Weighted average discount rate - operating leases 8.48%  Future annual minimum lease payments and finance lease commitments as of December 31, 2019 were as follows (in thousands) :         Operating Leases Finance Leases  2020 $ 1,063 $ 20  2021 1,054 20  2022 1,014 6  2023 1,022 -  2024 426 -  Thereafter - -  Total undiscounted future minimum lease payments 4,579 46  Less imputed interest 737 6  Lease liability $ 3,842 $ 40 

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Taxes [Abstract]
Income Taxes	Note 11 – Income Taxes New Tax Legislation  On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (“TCJA”). The legislation significantly changed U.S. tax law by, among other things, lowering the corporate income tax rate from 35% to 21% and changing the carryforward and utilization of net operating losses. We will monitor future interpretations of the TCJA as they develop, and accordingly our estimates may change.  As a result of the reduction in federal corporate income tax rates provisioned by the TCJA the Company recorded a reduction to its deferred tax assets of $19.0 million at December 31, 2017 and a corresponding reduction to its valuation allowa nce. The Company’s net deferred tax asset at December 31, 2019 and 2018 reflect the current reduced federal income tax rates. In addition, the Company will file a claim for a federal tax refund of approximately $0.2 million for its AMT credit carryforward in tax years 2018 to 2021 pursuant to the appl icable provisions of the TCJA.  Net loss before income taxes consists of the following (in thousands):    For the Years Ended  December 31,  2019 2018  Domestic, current $ (4,298) $ (9,542)  Total $ (4,298) $ (9,542) The tax effects of significant items comprising the Company’s deferred taxes are as follows (numbers are in thousands):     For the Years Ended  December 31,  2019 2018  Deferred tax assets:  Federal and state net operating loss carryforwards $ 30,428 $ 30,350  Research and development tax credit carryforwards 2,479 2,438  Stock based compensation 1,632 1,470  Other provision and expenses not currently deductible 1,327 1,345  Total deferred tax assets 35,866 35,603  Deferred tax liabilities:  Depreciation and amortization (693) (726)  Prepaid expenses (195) (151)  Total deferred liabilities (888) (877)  Less: valuation allowance (34,978) (34,726)  Net deferred tax asset $ — $ — The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The effect on deferred tax assets and liabilities of changes in tax rates will be recognized as income or expense in the period that the change occurs. A valuation allowance for deferred tax assets is recorded when it is more likely than not that some or all of the benefit from the deferred tax asset will not be realized. Changes in circumstances, assumptions and clarification of uncertain tax regimes may require changes to any valuation allowances associated with the Company’s deferred tax assets.  As of December 31, 2019 , the Company’s deferred tax assets were generated primarily from the federal and state net operating loss, stock based compensation and research and development tax credits. In assessing the realizability of deferred tax assets, management determined that it is more likely than not that none of the deferre d tax assets will be realized. Therefore, the Company has provided a full valuation allowance against the deferred tax assets at December 31, 2019 and 2018 .  As of December 31, 2019 and 2018 , the Company had net deferred tax assets before its valuation allowance of $35.0 million and $34.7 million , respectively. During the year ended December 31, 2019 , the Company did not utilize its prior years’ net operating loss carryforwards and the net operating loss of $5.3 million that originated in 1998 expired. As of December 31, 2019 , eMagin has federal and state net operating los s carryforwards of $142.7 million and federal research and development tax credit carryforwards of $2.5 million. Pursuant to provisions of the TCJA, the net operating losses originating in years subsequent to 2017 totaling $14.7 million can be carried forward indefinitely.  The federal net operating losses and tax credit carryforwards will expire as follows (in thousands) :     Net Research and  Operating Development  Losses Tax Credits  2019 -2020 $ 24,931 $ 653  2021 -2024 41,283 -  2025 -2037 61,755 1,826  No Expiration 14,705 -  $ 142,674 $ 2,479  The utilization of net operating losses can be subject to a limitation due to the change of ownership provisions under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result in the expiration of the net operating losses before their utilization. The Company has done an analysis regarding prior year ownership changes, and it has been determined that the Section 382 limitation on the utilization of net operating losses will currently not materially affect the Company's ability to utilize its net operating losses. The difference between the statutory federal income tax rate on the Company's pre-tax loss and the Company's effective income tax rate is summarized as follows:     For the Years Ended  December 31,  2019 2018  U.S. Federal income tax benefit at federal statutory rate 21 % 21 %  Change in valuation allowance (6) (21)  Permanent differences 7 (3)  NOL Expiration - 1998 (26) -  Other, net 4 3  Effective tax rate - % - %  The Company did no t have unrecognized tax benefits at December 31, 2019 and 2018 . The Company recognizes interest accrued and penalties related to unrecognized tax benefits in tax expense. During the years ended December 31, 2019 and 2018 , the Company recognized no interest and penalties. The Company files income tax returns in the U.S. federal jurisdiction and in certain U.S. states. Generally, the Company’s tax filings are subject to tax examinations by major taxing jurisdictions during the three years period subsequent to the due date of such returns, or if later, when the return is filed. However, d ue to the Company's operating losses, the utilization of a net operating loss subjects the year that such loss originated to being open for examination by major taxing jurisdictions to which the Company is subject.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2019
Warrants [Abstract]
Warrants	Note 12 – Warrants  The Company accounts for common stock warrants pursuant to applicable accounting guidance contained in ASC 815, "Derivatives and Hedging - Contracts in Entity's Own Equity" and makes a determination as to their treatment as either equity instruments or a warrant liability based on an analysis of the underlying warrant agreements.  Summary of warrants and warrants outstanding:     Issued Outstanding Exercise Price Expire  2015 Warrant Issuance 383,500 383,500 2.05 Jun 2021  2016 Warrant Issuance 2,947,949 2,947,949 2.60 Feb 2023  2017 Warrant Issuance (1)(2) 100,000 100,000 2.25 Mar 2022  2017 Warrant Issuance (1) 1,650,000 1,650,000 2.45 Nov 2022  2018 Warrant Issuance (1) 4,004,324 3,974,324 1.55 Jul 2023  2019 Warrant Issuance 240,000 240,000 0.55 Apr 2024  2019 Warrant Issuance (3) 4,000,000 4,000,000 0.49 Oct 2024  2019 Warrant Issuance (4) 6,000,000 6,000,000 0.78 Oct 2024  (1) W arrants are subject to liability accounting . (2) Issued in conjunction with an unsecured line of credit as described in Note 9: Debt / Line of Credit . (3) Immediately exercisable pre-funded warrants at an exercise price of $0.01 per share. (4) Private Placement u nregistered warrants exercisable six months following issuance .  Equity classified warrants  The 2015, 2016, and 2019 warrants share similar terms, and the exercise price of the Warrant Shares are subject to adjustment in the event of any stock dividends and splits, reverse stock splits, stock dividends, recapitalizations, reorganizations or similar transactions. The Warrants will be exercisable on a “cashless” basis in certain circumstances, including in the event a registration statement is not in effect at time of exercise. The warrant agreements contain a clause specifying that in the event there is no effective registration in effect for the underlying warrant shares to be issued at time of exercise, in no circumstance will the Company be required to net cash settle the warrants.  Based on the Company’s analysis of the terms and conditions of the warrants, the Company has concluded that they meet the conditions outlined in applicable accounting guidance to be classified as equity instruments. As a result, the Company has accounted for the exercise price paid by investors for purchase of the pre-funded warrants as additional paid in capital on the accompanying Balance Sheets as of December 31, 2019 .  Liability classified warrants  The 2017 and 2018 warrants have alternative settlement provisions that, at the option of the holder, provide for physical settlement or if, at the time of settlement there is no effective registration statement, a cashless exercise as defined in the warrant agreement.  Based on analysis of the underlying warrant agreement and applicable accounting guidance, the Company concluded that these registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. Accordingly, these warran ts were classified in the accompanying Consolidated Balance Sheet as a current liability upon issuance and will be revalued at each subsequent balance sheet date.  The fair value of the liability for common stock purchase warrants is estimated using the Black Scholes option pricing model based on the market value of the underlying common stock at the measurement date, the contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.  Based on the Black Sholes method the fair value of the Company’s warrants are as follows (in thousands) :     2019 2018  2018 January and February Issuance  Fair Value at December 31, $ 22 $ 1,342   2017 May issuance  Fair Value at December 31, 1 155  $ 23 $ 1,497    Twelve Months Ended  December 31,  Change in Fair Value of common stock warrant liability (1) $ 1,474 $ 2,194  (1) The combined changes in fair value is reflected as income from change in the fair market value of common stock warrant liability.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2019
Shareholders' Equity [Abstract]
Shareholders' Equity	Note 13 – Shareholders’ Equity  Preferred Stock - Series B Convertible Preferred Stock (“the Preferred Stock – Series B”)  The Company has designated 10,000 shares of the Company’s preferred stock as Preferred Stock – Series B at a stated value of $1,000 per share. The Preferred Stock – Series B is convertible into common stock at a conversion price of $0.75 per share. The holders of the Preferred Stock – Series B are not entitled to receive dividends unless the Company’s Board of Directors declare a dividend for holders of the Company’s common stock and then the dividend shall be equal to the amount that such holder would have been entitled to receive if the holder converted its Preferred Stock – Series B into shares of the Company’s common stock. In the event of a liquidation, dissolution, or winding up of the Company, the Preferred Stock – Series B is entitled to receive liquidation preference before the Common Stock. The Company may at its option redeem the Preferred Stock – Series B by providing the required notice to the holders of the Preferred Stock – Series B and paying an amount equal to $1,000 multiplied by the number of shares for all of such holder’s shares of outstanding Preferred Stock – Series B to be redeemed.  As of December 31, 2019 and 2018 , there were 5,659 shares of Preferred Stock – Series B i ssued and outstanding.  Common Stock  Common share activity due to o ption s and warrant s (dollar amounts in thousands):     Twelve Months Ended  December 31,  2019 2018  Options exercised 12,500 99,937  Proceeds $ 9 $ 98   Warrants exercised - 30,000  Proceeds $ - $ 46  Equity Issuances  On January 25, 2018 the Company entered into an underwriting agreement to issue and sell 9,807,105 shares of Company Common Stock, together with warrants to purchase 3,922,842 shares of Common Stock with an initial exercise price of $1.55 per share (at a public offering price of $1.35 per fixed combination consisting of one share of Common Stock and associated warrant to purchase four tenths of one share of Common Stock). The offering closed on January 29, 2018 and the Company received net proceeds after underwriting discounts and expenses of $11.9 million.  In a concurrent private placement, certain of our directors and officers purchased an aggregate of 203,708 shares of Common Stock, together with warrants to purchase up to 81,487 shares of Common Stock at the public offering price of $1.35 per fixed combination. The private placement closed on February 15, 2018 , and the Company received net proceeds of $0.3 million.  On April 9, 2019, the Company closed a registered direct offering of 4.0 million shares of common stock at a purchase price per share of $0.50 , for gross proceeds of approximately $2.0 million before deducting placement agent fees and other offering expenses. The Company also issued unregistered warrants to the investor to purchase up to 3.0 million shares of common stock at an exercise price of $0.78 per share. The warrants are exercisable nine months following issuance and will expire five and one-half years from the issuance date.  On April 11, 2019, the Company closed an additional $2.0 million registered direct offering consisting of immediately exercisable pre-funded warrants to purchase up to 4.0 million shares of our common stock at a purchase price of $0.49 per warrant and an exercise price of $0.01 per share. In a concurrent private placement, the Company also issued to the investor in the registered direct offering unregistered warrants to purchase up to 3.0 million shares of the Company’s common stock at an exercise price of $0.78 per share. The unregistered warrants are exercisable six months following issuance and will expire five and one-half years from the issuance date.  On November 22, 2019, the Company entered into an ATM offering agreement with H.C. Wainwright & Co., LLC, (“Wainwright”) relating to shares of our common stock. In accordance with the terms of the sales agreement, we may offer and sell up to 5.0 million shares of our common stock having an aggregate of fering price of up to $1.7 million from time to time through Wainwright acting as our sales agent. Wainwright will be entitled to compensation at a fixed commission rate equal to 3.0% of the gross proceeds per share sold under the sales agreement. We intend to use any net proceeds from this offering to fund working capital requirements and for other general corporate purposes.

Stock Compensation

Stock Compensation	12 Months Ended
	Dec. 31, 2019
Stock Compensation [Abstract]
Stock Compensation	Note 14 – Stock Compensation Employee stock purchase plan In 2005, the shareholders approved the 2005 Employee Stock Purchase Plan (“ESPP”). The ESPP provides the Company’s employees with the opportunity to purchase common stock through payroll deductions. Employees may purchase stock semi-annually at a price that is 85% of the fair market value at certain plan-defined dates. At December 31, 2016, the number of shares of common stock available for issuance was 300,000 . As of December 31, 2019 , the plan had not been implemented. Incentive compensation plans  The 2017 Incentive Stock Plan (the “2017 Plan”) adopted and approved by the shareholders on May 25, 2017 provides for grants of common stock and opt ions to purchase shares of common stock to employees, officers, directors and consultants. The 2017 Plan has an aggregate of 2.0 million shares. Vesting terms of the options range from immediate vesting to a ratable vesting period of 5 years.  The 2019 Employee and Consultant Stock Option and Incentive Plan (the “2019 Employee and Consultant Plan”) was adopted and approved by the shareholders on December 5, 2019 was designed to enhance the flexibili ty to grant equity awards to officers, employees and consultants and to ensure grant of equity awards to eligible recipients. The 2019 Plan has an aggregate of 5.0 million shares and permits an award of stock options (both incentive and non-qualified options), stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, dividend equivale nt rights and cash-based awards. A minimum vesting period of one year is required for all equity awards .  Option activity for the year ended December 31, 2019 is summarized as follows:     Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value  Outstanding at December 31, 2018 4,678,420 $ 2.81  Options granted 1,438,695 0.65  Options exercised (12,500) 0.70  Options forfeited (9,200) 2.66  Options cancelled or expired (690,430) 1.54  Outstanding at December 31, 2019 5,404,985 $ 2.40 3.52 $ —  Vested or expected to vest at December 31, 2019 (1) 5,401,528 $ 2.40 3.52 $ —  Exercisable at December 31, 2019 5,232,179 $ 2.40 3.52 $ —  (1) The expected to vest options are the result of applying the pre-vesting forfeiture rate assumptions to total unvested options.  At December 31, 2019 , there were 5.0 and 2.0 million shares available for grant under the 2019 Employee and Consultant and Non - Employee Director Incentive Plans and 49,834 shar es available for grant under the 2017 Plan. T here are no shares available for grant under older plans.  The aggregate intrinsic value in the table above represents the difference between the exercise price of the underlying options and the quoted price of the Company’s common stock on December 31, 2019 for the options that were in-the-money. As of December 31, 2019 there were no options that were in-the-money. The Company’s closing stock price was $0.34 as of December 31, 2019 . The Company issues new shares of common stock upon exercise of stock options. The intrinsic value of options exercised was $2.0 thousand for the year ended December 31, 2019 .  Stock- based compensation The Company uses the fair value method of accounting for share-based compensation arrangements. The fair value of stock options is estimated at the date of grant using the Black-Scholes option valuation model. Stock-based compensation expense is reduced for estimated forfeitures and is amortized over the vesting period using the straight-line method.  The following table summarizes the allocation of non-cash stock-based compensation to the Company’s expense categories for the years ended December 31, 2019 and 2018 (in thousands):    Twelve Months Ended  December 31,  2019 2018  Cost of revenues $ 25 $ 36  Research and development 85 95  Selling, general and administrative 441 479  Total stock compensation expense $ 551 $ 610  At December 31, 2019 , total unrecognized compensation costs related to stock options was approximately $0.4 million, net of estimated forfeitures. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures and is expected to be recognized over a weighted average period of approximately 0.7 years.  The following key assumptions were used in the Black-Scholes option pricing model to determine the fair value of stock options granted:     Twelve Months Ended  December 31,  2019 2018  Dividend yield 0 % 0 %  Risk free interest rates 1.77 -2.48 % 2.16 -2.75 %  Expected volatility 41.7 to 49.2 % 46.4 to 50.0 %  Expected term (in years) 3.5 to 4.0 3.5 to 4.8  The weighted average fair value per share for options granted in 2019 and 2018 was $0.65 and $1.70 , respectively.  There were no dividends declared or paid in 2019 or 2018 . The Company does not expect to pay dividends in the near future; therefore, it used an expected dividend yield of 0% . The risk-free interest rate used in the Black-Scholes option pricing model is based on the implied yield at the time of grant available on U.S. Treasury securities with an equivalent term. Expected volatility is based on the weighted average historical volatility of the Company’s common stock for the equivalent term. The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience and vesting schedules of similar awards.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 15 – Commitments and Contingencies Equipment Purchase Commitments The Company has committed to equipment purchases of approximately $ 0.3 million at December 31, 2019 .  Employee benefit plans The Company’s U.S. employees participate in a defined contribution plan. Under the provisions of the plan, an employee is fully vested with respect to Company contributions after five years of service. The Company matches employee contributions of 50 % up to a maximum of 3% of qualified compensation. The Company’s contributions were $0.1 million for the year ended December 31, 2019 and there were no Company contributions for the years ended December 31, 2018 .  Change in Control agreements  The Company entered into change in control agreements with certain of its executive officers, non-executive officers and managers. The agreements specify various employment-related matters, including annual compensation, performance incentive bonuses, and severance benefits in the event of termination with or without cause.  Litigation  From time to time, the Company is subject to various legal proceedings and claims that arise in the ordinary course of business. In March 2019, we received a demand letter seeking payment of $0.9 million of outstanding invoices relating to purchased inventory from Suga Electronics Limited, or Suga, a contract manufacturer located in China, which manufactured product sold by their consumer night vision business. We responded to the demand letter, and requested that Suga provide substant iation of purchased inventory.  During September and October 2019, the Company held discussions with Suga to attempt to reach a settlement; however, in November 2019 the Company received a formal request for arbitration which Suga filed with the International Chamber of Commerce or ICC. The Company retained local counsel in Hong Kong to represent it before the ICC and in December 2019 filed an answer to Suga’s request for arbitration including a counterclaim seeking repayment of amounts previously paid to Suga. The parties are currently awaiting the appointment of an arbitrator by the ICC.  As disclosed, during the quarter ended June 30, 2018, we made a decision to exit the consumer night vision business and accrued approximately $1.0 million related to invoices received for inventory purchased by Suga in anticipation of future production. While we believe that we have adequately accrued for the losses and are in discussions to resolve related claims by the contract manufacturers, there is the risk that additional losses or litigation related expenses may be incurred above the amounts accrued for as of December 31, 2019, if we fail to resolve these claims in a timely and/or favorable manner. 

Quarterly Financial Information

Quarterly Financial Information	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information [Abstract]
Quarterly Financial Information	Note 16 – Quarterly Financial Information (Unaudited) Summarized quarterly financial information for 2019 and 2018 are as follows (in thousands except share data):     Quarters Ended  March 31, June 30, September 30, December 31,  2019 2019 2019 2019  Revenues $ 6,112 $ 5,361 $ 7,919 $ 7,334  Gross profit $ 1,336 $ 225 $ 2,491 $ 2,676  Net income (loss) before income tax $ (1,439) $ (2,337) $ (315) $ (207)  Net loss $ (1,439) $ (2,337) $ (315) $ (207)  Net loss per share - basic $ (0.03) $ (0.05) $ (0.01) $ (0.00)  Net loss per share - diluted $ (0.03) $ (0.05) $ (0.01) $ (0.00)  Weighted average number of shares outstanding - basic 45,161,273 48,817,940 49,173,773 49,316,852  Weighted average number of shares outstanding - diluted 45,161,273 48,817,940 49,173,773 49,316,852     Quarters Ended  March 31, June 30, September 30, December 31,  2018 2018 2018 2018  Revenues $ 6,867 $ 7,066 $ 6,867 $ 5,435  Gross profit $ 1,980 $ 106 $ 2,379 $ (471)  Net loss before income tax $ (2,081) $ (5,065) $ 63 $ (2,459)  Net loss $ (2,081) $ (5,065) $ 63 $ (2,459)  Net loss per share - basic $ (0.05) $ (0.11) $ 0.00 $ (0.05)  Net loss per share - diluted $ (0.05) $ (0.11) $ 0.00 $ (0.05)  Weighted average number of shares outstanding - basic 42,255,189 45,111,273 45,149,717 45,161,273  Weighted average number of shares outstanding - diluted 42,255,189 45,111,273 45,265,370 45,161,273 

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 17 – Subsequent Events  On February 13 , 2020, we have entered into a n amendment to the ATM o ffering a greement , dated November 22, 2019 , with Wainwright. The Amendment modifies the Agreement to amend the aggregate offering price up to $2.5 million of the shares that the Company may offer and sell through Wainwright from time to time . Wainwright will be entitled to reimbursement up to $15 thousand under the sales agreement. We intend to use the net proceeds from this offering to fund working capital requirements and for other general corporate purposes. 

Significant Accounting Polici_2

Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2019
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation  The accompanying consolidated financial statements include the accounts of eMagin Corporation and its wholly owned subsidiary. All intercompany transactions have been eliminated in consolidation. The Company manages its operations on a consolidated, integrated basis in order to optimize its equipment and facilities and to effectively service its global customer base, and concludes that it operates in a single business segment.
Use of Estimates	Use of Estimates  In accordance with accounting principles generally accepted in the United States of America, management utilizes certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments related to, among others, allowance for doubtful accounts, warranty reserves, inventory reserves, stock-based compensation expense, deferred tax asset valuation allowances, litigation and other loss contingencies. Management bases its estimates and judgments on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Revenue and Cost Recognition	Revenue and Cost Recognition  All of the Company’s revenues are earned from contracts with customers and are classified as either Product or Contract revenues. Contracts include written agreements and purchase orders, as well as arrangements that are implied by customary practices or law.  Product revenue is generated primarily from contracts to produce, ship and deliver OLED microdisplays. eMagin’s performance obligations are satisfied, control of our products is transferred, and revenue is recognized at a single point in time when control transfers to our customer for product shipped. Our customary terms are FOB our factory and control is deemed to transfer upon shipment. The Company has elected to treat shipping and other transportation costs charged to customers as fulfillment activities and are recorded in both revenue and cost of sales at the time control is transferred to the customer. As customers are invoiced at the time control transfers and the right to consideration is unconditional at that time, the Company does not maintain contract asset balances for product revenue. Additionally, the Company does not maintain contract liability balances for product revenues, as performance obligations are satisfied prior to customer payment for product. The Company offers a one-year product warranty, for replacement of product only, and does not allow returns. The Company offers industry standard payment terms that typically require payment from our customers from 30 to 60 days after title transfers.  The Company also recognizes revenues under the over time method from certain research and development (“R&D”) activities (contract revenues) under both firm fixed-price contracts and cost-type contracts. Progress and revenues from research and development activities relating to firm fixed-price contracts and cost-type contracts are generally recognized on an input method of accounting as costs are incurred. Under the input method, revenue is recognized based on efforts expended to date (e.g., the costs of resources consumed or labor hours worked, or machine hours used) relative to total efforts intended to be expended. Contract costs include all direct material, labor and subcontractor costs and an allocation of allowable indirect costs as defined by each contract, as periodically adjusted to reflect revised agreed upon rates. These rates are subject to audit by the other party. Any changes in estimate related to contract accounting are accounted for prospectively over the remaining life of the contract. Under the over time method, billings may not correlate directly to the revenue recognized. Based upon the terms of the specific contract, billings may be in excess of the revenue recognized, in which case the amounts are included in deferred revenues as a liability on the Consolidated Balance Sheets. Likewise, revenue recognized may exceed customer billings in which case the amounts are reported as unbilled receivables. Unbilled revenues are expected to be billed and collected within one year. The incidental costs related to obtaining product sales contracts are non-recoverable from customers; and accordingly, are expensed as incurred.  The Company adopted the provisions of ASC No. 606, Revenue from Contracts with Customers, and related amendments (“ASC 606”) on January 1, 2018 using the modified retrospective adoption method with the cumulative effect of initially applying the guidance recognized at the date of initial application. During 2017, the Company analyzed its revenue recognition policies under ASC 606 and then current revenue recognition policies and determined that the performance obligations, transaction price, allocation of transaction price, recognition of contract costs and timing of revenue recognition would not be materially impacted by adopting ASC 606. Accordingly, there was no modified retrospective adoption adjustment necessary as of January 1, 2018 .
Product Warranty	Product Warranty  The Company offers a one-year product replacement warranty. The standard policy is to repair or replace the defective products. The Company accrues for estimated returns of defective products at the time revenue is recognized based on historical activity as well as for specific known product issues. The determination of these accruals requires the Company to make estimates of the frequency and extent of warranty activity and estimate future costs to replace the products under warranty. If the actual warranty activity and/or repair and replacement costs differ significantly from these estimates, adjustments to cost of revenue may be required in future periods.  The following table provides a summary of the activity related to the Company's warranty liability, included in other current liabilities, during the years ended December 31, 2019 and 2018 (in thousands):      Twelve Months Ended  December 31,  2019 2018  Beginning balance $ 423 $ 468  Warranty accruals and adjustments 58 132  Warranty claims (181) (177)  Ending balance $ 300 $ 423 
Research and Development Expenses	Research and Development Expenses  Research and development costs are expensed as incurred.
Cash and Cash Equivalents	Cash and Cash Equivalents  All highly liquid instruments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents.
Accounts Receivable	Accounts Receivable  The majority of the Company’s commercial accounts receivable are due from Original Equipment Manufacturers ("OEM’s”). Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are payable in U.S. dollars, are due within 30 - 90 days and are stated at amounts due from customers net of an allowance for doubtful accounts. Any account outstanding longer than the contractual payment terms is considered past due.
Unbilled Accounts Receivable	Unbilled Accounts Receivable  Unbilled receivables principally represent revenues recorded under the over time method of accounting that have not been billed to customers in accordance with the contractual terms of the arrangement. We anticipate that the majority of the balance at December 31, 2019 will be collected during the 2020 fiscal year. As of December 31, 2019 and 2018 , unbilled accounts receivable was $0.2 million and $ 0.2 million, respectively.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts  The allowance for doubtful accounts reflects an estimate of probable losses inherent in the accounts receivable balance. The allowance is determined based on a variety of factors, including the length of time receivables are past due, historical experience, the customer's current ability to pay its obligation, and the condition of the general economy and the industry as a whole. The Company will record a specific reserve for individual accounts when the Company becomes aware of a customer's inability to meet its financial obligations, deterioration in the customer's operating results or financial position, or deterioration in the customer’s credit history. If circumstances related to customers change, the Company would further adjust estimates of the recoverability of receivables. Account balances, when determined to be uncollectible, are charged against the allowance.
Inventories	Inventories  Inventories are stated on a standard cost basis adjusted to approximate the lower of cost (as determined by the first-in, first-out method) or net realizable value. Cost includes materials, labor, and manufacturing overhead related to the purchase and production of inventories. The Company regularly reviews inventory quantities on hand, future purchase commitments with the Company’s suppliers, and the estimated utility of the inventory. If the Company review indicates a reduction in utility below carrying value, the inventory is reduced to a new cost basis.
Equipment, Furniture and Leasehold Improvements	Equipment, Furniture and Leasehold Improvements  Equipment, furniture and leasehold improvements are stated at cost. Depreciation on equipment is calculated using the straight-line method of depreciation over the estimated useful life ranging from three to 10 years. Amortization of leasehold improvements is calculated by using the straight-line method over the shorter of their estimated useful lives or lease terms. Expenditures for maintenance and repairs are charged to expense as incurred. The Company performs impairment tests on its long-lived assets when circumstances indicate that their carrying amounts may not be recoverable. If required, recoverability is tested by comparing the estimated future undiscounted cash flows of the asset or asset group to its carrying value. Impairment losses, if any, are recognized based on the excess of the assets' carrying amounts over their estimated fair values.
Intangible Assets - Patents	Intangible Assets - Patents  Acquired patents are recorded at purchase price as of the date acquired and amortized over the expected useful life which is generally the remaining life of the patent. Total intangible amortization expense was approximately $32 and $54 thousand for the years ended December 31, 2019 and 2018 , respectively.   
Advertising	Advertising  Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. There was no advertising expense for the years ended December 31, 2019 and 2018 .
Shipping and Handling Fees	Shipping and Handling Fees  The Company includes costs related to shipping and handling in cost of goods sold. 
Income Taxes	 Income Taxes  The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The effect on deferred tax assets and liabilities of changes in tax rates will be recognized as income or expense in the period that the change occurs. The Company recognizes the effect of income tax positions which are more-likely-than-not of being sustained. A valuation allowance for deferred tax assets is recorded when it is more likely than not that some or all of the benefit from the deferred tax asset will not be realized. Changes in circumstances, assumptions and clarification of uncertain tax regimes may require changes to any valuation allowances associated with the Company’s deferred tax assets.  Due to the Company’s operating loss carryforwards, all tax years remain open to examination by the major taxing jurisdictions to which the Company is subject. In the event that the Company is assessed interest or penalties at some point in the future, it will be classified in the financial statements as tax expense .  For additional details regarding our accounting for income taxes, see Note 11 in the accompanying consolidated financial statements.
Net Loss per Common Share	Net Loss per Common Share  Basic loss per share is computed using the weighted average number of common shares outstanding during the period, and excludes any dilutive effects of common stock equivalent shares such as stock options, warrants, and convertible preferred stock. Diluted loss per share is computed using the weighted average number of common shares outstanding and potentially dilutive common stock equivalent shares outstanding during the period. Common stock equivalent shares are excluded from the computation if their effect is anti-dilutive.  In accordance with Accounting Standards Codification (“ASC”) 260, entities that have issued securities other than common stock that participate in dividends with the common stock (“participating securities”) are required to apply the two-class method to compute basic EPS. The two-class method is an earnings allocation method under which EPS is calculated for each class of common stock and participating security as if all such earnings had been distributed during the period.  The Company’s Series B Convertible Preferred stock (“Preferred Stock – Series B”) is considered a participating security as the preferred stock participates in dividends with the common stock, which requires the use of the two-class method when computing basic and diluted earnings per share. The Preferred Stock – Series B is not required to absorb any net loss. Although the Company paid a one-time special dividend in 2012, the Company does not expect to pay dividends on its common or preferred stock in the near future.  For the years ended December 31, 2019 and 2018 , the Company reported a net loss and as a result, basic and diluted loss per common share are the same. Therefore, in calculating net loss per share amounts, shares underlying the potentially dilutive common stock equivalents were excluded from the calculation of diluted net income per common share because their effect was anti-dilutive.  The following is a table of the potentially dilutive common stock equivalents for the years ended December 31, 2019 and 2018 that were not included in diluted EPS as their effect would be anti-dilutive:      Twelve Months Ended  December 31,  2019 2018  Options 5,404,985 4,678,420  Warrants 19,295,773 9,055,773  Convertible preferred stock 7,545,333 7,545,333  Total potentially dilutive common stock equivalents 32,246,091 21,279,526  
Comprehensive Income (Loss)	Comprehensive Income (loss)  Comprehensive income (loss) refers to net income (loss) and other revenue, expenses, gains and losses that, under generally accepted accounting principles, are recorded as an element of shareholders’ equity but are excluded from the calculation of net income (loss). The Company's operations did not give rise to any material items includable in comprehensive income (loss), which were not already in net income (loss) for the years ended December 31, 2019 and 2018 . Accordingly, the Company's comprehensive income (loss) is the same as its net income (loss) for the periods presented.
Fair Value of Financial Instruments	Fair Value of Financial Instruments  Cash, cash equivalents, accounts receivable, short-term investments and accounts payable are stated at cost, which approximates fair value due to the short-term nature of these instruments. The Asset Based Lending Facility, (“ABL Facility”) is also stated at cost, which approximates fair value because the interest rate is based on a market based rate plus a margin.  We have categorized our assets and liabilities that are valued at fair value on a recurring basis into three-level fair value hierarchy in accordance with GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows: Level 1 – Unadjusted quoted prices in active markets of identical assets or liabilities. Level 2 – Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 – Unobservable inputs for the asset or liability. The common stock warrant liability discussed in Note 12 is currently the only financial assets or liability recorded at fair value on a recurring basis, and is considered a Level 3 liability. The fair value of the common stock warrant liability is included in current liabilities on the accompanying financial statements as of December 31, 2019 , as the warrants are currently exercisable  The following table shows the reconciliation of the Level 3 warrant liability measured and recorded at fair value on a recurring basis, using significant unobservable inputs (in thousands):     Estimated Fair Value  Balance as of January 1, 2019 $ 1,497  Fair value of warrants issuance during period -  Change in fair value of warrant liability, net (1,474)  Balance as of December 31, 2019 $ 23  The fair value of the liability for common stock purchase warrants at December 31, 2019 was estimated using the Black Scholes option pricing model based on the market value of the underlying common stock at the measurement date, the five year contractual term of the warrants, risk-free interest rates of 1.56% , no expected dividends and expected volatility of the price of the underlying common stock ranging from 40.3 % to 46.4% .
Stock-Based Compensation	Stock-based Compensation  The Company uses the fair value method of accounting for share-based compensation arrangements. The fair values of stock options are estimated at the date of grant using the Black-Scholes option valuation model. Stock-based compensation expense is reduced for estimated forfeitures and is amortized over the vesting period using the straight-line method.
Derivative Financial Instruments	Derivative Financial Instruments  The Company evaluates all financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features qualifying as embedded derivatives. For derivative financial instruments accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statement of operations. The Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.
Concentration of Credit Risk and Concentrations	Concentration of Credit Risk  The majority of eMagin’s products are sold throughout North America, Asia, and Europe. Sales to the Company’s recurring customers are made generally on open account while sales to occasional customers are typically made on a prepaid basis. eMagin performs periodic credit evaluations on its recurring customers and generally does not require collateral. An allowance for doubtful accounts is maintained for credit losses.  Financial instruments which potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents and short-term investments. The Company’s cash and cash equivalents are deposited with financial institutions which, at times, may exceed federally insured limits. The Company invests surplus cash in a government money market fund that consists of U.S Government obligations and repurchase agreements collateralized by U.S. Government Obligations, which is not insured. To date, the Company has not experienced any loss associated with this risk.  Concentrations  The Company purchases principally all of its silicon wafers, which are a key ingredient in its OLED production process, from two suppliers located in Taiwan and Korea.  For the year ended December 31, 2019 and 2018 , no single customer accounted for over 10% of net revenues.
Liquidity and Going Concern	Liquidity and Going Concern  The accompanying consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue to operate as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. For the year ended December 31, 2019 , the Company incurred a net loss of $4.3 million and used cash in operating activities of $5.1 million. At December 31, 2019 , the Company had cash and cash equivalents of $3.5 million, net working capital of $8.8 million, outstanding debt of $2.9 million, and outstanding borrowing availability under its ABL Facility of $1.2 million.  Due to continuing losses, the Company’s financial position, and uncertainty regarding the Company’s ability to borrow under its ABL Facility, or continue to raise funds under its ATM facility, the Company may not be able to meet its financial obligations as they become due without additional financing or sources of capital. Management is prepared to reduce expenses and raise additional capital, but there can be no assurance that the Company will be successful in sufficiently reducing expenses or raising capital to meet its operating needs.  The Company’s ABL Facility expires on December 31, 2020 and renews automatically for another year unless terminated pursuant to its terms. Although our relationship with the lender is positive, there is no assurance the lender will renew or extend this facility, or continue to make funds available during 2020 and beyond at present availability levels, or at all. Therefore, in accordance with applicable accounting guidance, and based on the Company’s current financial condition and availability of funds, there is substantial doubt about the Company’s ability to continue as a going concern through twelve months from the date these financial statements were issued.  The Company has taken actions to increase revenues and to reduce expenses and is considering financing alternatives, but there can be no assurance that the Company will be successful in sufficiently increasing revenues, reducing expenses or securing additional financing to meet its operating needs. The Company’s plans with regard to these matters include the following actions: 1) focus production and engineering resources on improving manufacturing yields and increasing production volumes, 2) a senior management Work Status Reduction , 3) reduce headcount and not replace departed employees, 4) reduce discretionary and other expenses, and 5) considering financing and/or strategic alternatives. In October 2019, senior management work status was reduced by approximately 20% under a work status r eduction program.  Based on the Company’s current projections, operational and yield improvements, and the anticipated availability of the ABL Facility, the Company estimates it will have sufficient liquidity to fund operations through the end of the fourth quarter of 2020 . However. there can be no assurance the Company’s plans will be achieved, or that the Company will be able to continue to borrow under its ABL Facility, continue to raise funds under its ATM facility, secure additional financing, and/or pursue strategic alternatives on terms acceptable to the Company, or at all.
Accounting Policy Updates, Recently Adopted Accounting Standards and Recently Issued Accounting Standards	Accounting Policy Updates  The Company adopted Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842) on January 1, 2019. The Company evaluates whether leases are classified as operating or financing based on certain assumptions that require judgment, such as the asset's fair value, the asset's estimated residual value, the interest rate implicit in the lease, and the asset's economic useful life.  At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use (“ROU”) assets upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company records lease liabilities within current or noncurrent liabilities based upon the length of time associated with the lease payments. The operating lease ROU assets includes any lease payments made and excludes lease incentives and initial direct costs incurred, if any, and are recorded as noncurrent assets. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.  Leases with an initial term of 12 months or less are not recorded on the accompanying consolidated balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.  Equipment under capital lease obligations are classified as revenue earning assets and the related depreciation is recorded on the assets. Debt related to capital lease obligations is included in the Company’s debt obligations.  Recently Adopted Accounting Standards  In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532 - Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The Company adopted the guidance on January 1, 2019, and such adoption did not have a material impact on its financial statements.  In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) and subsequently issued amendments that replaced existing lease accounting guidance. The accounting standard requires lessees to recognize a lease liability and corresponding right-of-use asset on their balance sheets. The Company adopted the guidance effective January 1, 2019. The Company elected the transition package of three practical expedients permitted under the transition guidance and elected the optional transition method that allows for a cumulative-effect adjustment in the period of adoption, without a restatement of prior periods.  As a result of the adoption, the Company adjusted its beginning balance at January 1, 2019 by recording operating lease ROU assets and liabilities through a cumulative-effect adjustment. The adoption impacted the accompanying consolidated balance sheet, but did not have an impact on the consolidated statements of operations and comprehensive loss.  The impact of the adoption of ASC 842 on the accompanying consolidated balance sheet as of January 1, 2019 was as follows (in thousands.     December 31, 2018 Adjustments Due to the Adoption of ASC 842 January 1, 2019  Right of Use Assets (1)  Operating lease - right of use asset $ — $ 4,267 $ 4,267   Operating lease liabilities  Current $ — $ 964 $ 964  Noncurrent $ — $ 3,432 $ 3,432  (1) Operating lease right-of-use assets includes deferred rent of $129 thousand  Recently Issued Accounting Standards  In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) and subsequently issued amendments. The guidance affects the Company's accounts receivable, and it requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. This new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. Based on the composition of the Company's receivables, current market conditions and historical credit loss activity, the Company does not expect the adoption of this ASU to have a significant impact on the consolidated financial statements.  In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) a guidance that adds, amends, and removes certain disclosure requirements related to fair value measurements. Among other changes, this standard requires certain additional disclosure surrounding Level 3 assets, including changes in unrealized gains or losses in other comprehensive income and certain inputs in those measurements. This new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Certain amended or eliminated disclosures in this standard may be adopted early, while certain additional disclosure requirements in this standard can be adopted on its effective date. In addition, certain changes in the standard require retrospective adoption, while other changes must be adopted prospectively. The Company is currently evaluating the impact of this guidance on the Company’s disclosures; however, the Company does not expect the adoption of this ASU to have a significant impact on the consolidated financial statements.  In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) as part of its initiative to reduce complexity in accounting standards. This standard simplify the accounting for income taxes. This new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. This standard may be adopted early, while certain additional disclosure requirements in this standard can be adopted on its effective date. In addition, certain changes in the standard require retrospective adoption, while other changes must be adopted prospectively. The Company is currently evaluating the impact of this guidance on the Company’s disclosures; however, the Company does not expect the adoption of this ASU to have a significant impact on the consolidated financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Significant Accounting Policies [Abstract]
Summary of Activity Related to Warranty Liability Included in Other Current Liabilities	  Twelve Months Ended  December 31,  2019 2018  Beginning balance $ 423 $ 468  Warranty accruals and adjustments 58 132  Warranty claims (181) (177)  Ending balance $ 300 $ 423 
Schedule of Potentially Dilutive Common Stock Equivalents	   Twelve Months Ended  December 31,  2019 2018  Options 5,404,985 4,678,420  Warrants 19,295,773 9,055,773  Convertible preferred stock 7,545,333 7,545,333  Total potentially dilutive common stock equivalents 32,246,091 21,279,526 
Reconciliation of the Level 3 Warrant Liability Measured and Recorded at Fair Value on a Recurring Basis	  Estimated Fair Value  Balance as of January 1, 2019 $ 1,497  Fair value of warrants issuance during period -  Change in fair value of warrant liability, net (1,474)  Balance as of December 31, 2019 $ 23 
Impact of Adoption of ASC 842 on Balance Sheet	  December 31, 2018 Adjustments Due to the Adoption of ASC 842 January 1, 2019  Right of Use Assets (1)  Operating lease - right of use asset $ — $ 4,267 $ 4,267   Operating lease liabilities  Current $ — $ 964 $ 964  Noncurrent $ — $ 3,432 $ 3,432  (1) Operating lease right-of-use assets includes deferred rent of $129 thousand

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2019
Revenue Recognition [Abstract]
Schedule of Disaggregated Revenue	   Twelve Months Ended  December 31,  2019 2018  North and South America $ 14,566 $ 13,969  Europe, Middle East, and Africa 11,112 9,157  Asia Pacific 1,048 3,109  Total $ 26,726 $ 26,235     Twelve Months Ended  December 31,  2019 2018  Military 65 % 75 %  Commercial, including industrial and medical 12 % 10 %  Consumer 4 % 6 %  Multiple 19 % 9 %  100 % 100 % 
Schedule of Contract Assets and Liabilities	  December 31, December 31,  2019 2018  Unbilled Receivables (contract assets) $ 155 $ 224   Deferred Revenue (contract liabilities) $ (277) $ (38) 

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Accounts Receivable, Net [Abstract]
Schedule of Accounts Receivable	   December 31, December 31,  2019 2018  Accounts receivable $ 4,105 $ 3,325  Less allowance for doubtful accounts (139) (139)  Accounts receivable, net $ 3,966 $ 3,186 

Inventories, Net (Tables)

Inventories, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Inventories, Net [Abstract]
Schedule of Components of Inventories	   December 31, December 31,  2019 2018  Raw materials $ 2,788 $ 3,701  Work in process 1,561 1,033  Finished goods 5,248 4,888  Total inventories 9,597 9,622  Less inventory reserve (765) (1,040)  Total inventories, net $ 8,832 $ 8,582 

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Prepaid Expenses and Other Current Assets [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	  December 31,  2019 2018  Vendor prepayments $ 657 $ 702  Other prepaid expenses 473 173  Total prepaid expenses and other current assets $ 1,130 $ 875 

Equipment, Furniture and Leas_2

Equipment, Furniture and Leasehold Improvements (Tables)	12 Months Ended
	Dec. 31, 2019
Equipment, Furniture and Leasehold Improvements [Abstract]
Schedule of Equipment, Furniture and Leasehold Improvements	  December 31,  2019 2018  Computer hardware and software $ 893 $ 800  Lab and factory equipment 17,482 17,107  Furniture, fixtures and office equipment 59 48  Assets under capital leases 116 66  Construction in progress 2,668 2,114  Leasehold improvements 60 22  Total equipment, furniture and leasehold improvements 21,278 20,157  Less: accumulated depreciation (13,178) (11,236)  Equipment, furniture and leasehold improvements, net $ 8,100 $ 8,921 

Debt _ Line of Credit (Tables)

Debt / Line of Credit (Tables)	12 Months Ended
	Dec. 31, 2019
Debt / Line of Credit [Abstract]
Schedule of Line of Credit	  (in thousands) 2019 2018  Revolving credit facility $ 2,891 $ —  Less: unamortized debt issuance costs — —  Revolving credit facility, net $ 2,891 $ — 

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Components of Lease Expense	  Twelve Months Ended  December 31, 2019  Finance Lease Cost:  Amortization of right-of-use assets $ 11  Interest on lease liabilities 3  Operating lease cost 986  Short-term lease cost 58  Total Lease Cost $ 1,058 
Schedule of Other Information	   Other Information  Cash paid for amounts included in the measurement lease liabilities:  Operating cash flows from operating leases $ 1,012  Financing cash flows from finance leases $ 13  Right-of-use assets obtained in exchange for new finance lease liabilities $ 50  Right-of-use assets obtained in exchange for new operating lease liabilities $ 110     December 31, 2019  Finance lease right-of-use assets $ 40  Operating lease right-of-use assets $ 3,729  Finance lease liability, current $ 16  Finance lease liability, non-current $ 24  Operating lease liabilities, current $ 775  Operating lease liabilities, non-current $ 3,067  Weighted average remaining lease terms - finance leases 2.33 years  Weighted average remaining lease terms - operating leases 4.42 years  Weighted average discount rate - finance leases 10.91%  Weighted average discount rate - operating leases 8.48% 
Future Annual Minimum Lease Payments and Finance Lease Commitments	  Operating Leases Finance Leases  2020 $ 1,063 $ 20  2021 1,054 20  2022 1,014 6  2023 1,022 -  2024 426 -  Thereafter - -  Total undiscounted future minimum lease payments 4,579 46  Less imputed interest 737 6  Lease liability $ 3,842 $ 40 

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Taxes [Abstract]
Schedule of Net Loss Before Income Taxes	  For the Years Ended  December 31,  2019 2018  Domestic, current $ (4,298) $ (9,542)  Total $ (4,298) $ (9,542) 
Schedule of Deferred Taxes	  For the Years Ended  December 31,  2019 2018  Deferred tax assets:  Federal and state net operating loss carryforwards $ 30,428 $ 30,350  Research and development tax credit carryforwards 2,479 2,438  Stock based compensation 1,632 1,470  Other provision and expenses not currently deductible 1,327 1,345  Total deferred tax assets 35,866 35,603  Deferred tax liabilities:  Depreciation and amortization (693) (726)  Prepaid expenses (195) (151)  Total deferred liabilities (888) (877)  Less: valuation allowance (34,978) (34,726)  Net deferred tax asset $ — $ — 
Schedule of Federal Net Operating Losses and Tax Credit Carryforwards	  Net Research and  Operating Development  Losses Tax Credits  2019 -2020 $ 24,931 $ 653  2021 -2024 41,283 -  2025 -2037 61,755 1,826  No Expiration 14,705 -  $ 142,674 $ 2,479 
Schedule of Reconciliation of Effective Tax Rate	  For the Years Ended  December 31,  2019 2018  U.S. Federal income tax benefit at federal statutory rate 21 % 21 %  Change in valuation allowance (6) (21)  Permanent differences 7 (3)  NOL Expiration - 1998 (26) -  Other, net 4 3  Effective tax rate - % - % 

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2019
Warrants [Abstract]
Summary of Warrants Issued and Warrants Outstanding	    Issued Outstanding Exercise Price Expire  2015 Warrant Issuance 383,500 383,500 2.05 Jun 2021  2016 Warrant Issuance 2,947,949 2,947,949 2.60 Feb 2023  2017 Warrant Issuance (1)(2) 100,000 100,000 2.25 Mar 2022  2017 Warrant Issuance (1) 1,650,000 1,650,000 2.45 Nov 2022  2018 Warrant Issuance (1) 4,004,324 3,974,324 1.55 Jul 2023  2019 Warrant Issuance 240,000 240,000 0.55 Apr 2024  2019 Warrant Issuance (3) 4,000,000 4,000,000 0.49 Oct 2024  2019 Warrant Issuance (4) 6,000,000 6,000,000 0.78 Oct 2024  (1) W arrants are subject to liability accounting . (2) Issued in conjunction with an unsecured line of credit as described in Note 9: Debt / Line of Credit . (3) Immediately exercisable pre-funded warrants at an exercise price of $0.01 per share. (4) Private Placement u nregistered warrants exercisable six months following issuance .
Fair Value of Warrants	    2019 2018  2018 January and February Issuance  Fair Value at December 31, $ 22 $ 1,342   2017 May issuance  Fair Value at December 31, 1 155  $ 23 $ 1,497    Twelve Months Ended  December 31,  Change in Fair Value of common stock warrant liability (1) $ 1,474 $ 2,194  (1) The combined changes in fair value is reflected as income from change in the fair market value of common stock warrant liability.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Shareholders' Equity [Abstract]
Common Share Activity	  Twelve Months Ended  December 31,  2019 2018  Options exercised 12,500 99,937  Proceeds $ 9 $ 98   Warrants exercised - 30,000  Proceeds $ - $ 46 

Stock Compensation (Tables)

Stock Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Stock Compensation [Abstract]
Schedule of Option Activity	   Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value  Outstanding at December 31, 2018 4,678,420 $ 2.81  Options granted 1,438,695 0.65  Options exercised (12,500) 0.70  Options forfeited (9,200) 2.66  Options cancelled or expired (690,430) 1.54  Outstanding at December 31, 2019 5,404,985 $ 2.40 3.52 $ —  Vested or expected to vest at December 31, 2019 (1) 5,401,528 $ 2.40 3.52 $ —  Exercisable at December 31, 2019 5,232,179 $ 2.40 3.52 $ —  (1) The expected to vest options are the result of applying the pre-vesting forfeiture rate assumptions to total unvested options.
Schedule of Allocation of Non-Cash Stock-Based Compensation	  Twelve Months Ended  December 31,  2019 2018  Cost of revenues $ 25 $ 36  Research and development 85 95  Selling, general and administrative 441 479  Total stock compensation expense $ 551 $ 610 
Schedule of Key Assumptions of Fair Value of Stock Options Granted	   Twelve Months Ended  December 31,  2019 2018  Dividend yield 0 % 0 %  Risk free interest rates 1.77 -2.48 % 2.16 -2.75 %  Expected volatility 41.7 to 49.2 % 46.4 to 50.0 %  Expected term (in years) 3.5 to 4.0 3.5 to 4.8 

Quarterly Financial Informati_2

Quarterly Financial Information (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information [Abstract]
Schedule of Quarterly Financial Information	 Quarters Ended  March 31, June 30, September 30, December 31,  2019 2019 2019 2019  Revenues $ 6,112 $ 5,361 $ 7,919 $ 7,334  Gross profit $ 1,336 $ 225 $ 2,491 $ 2,676  Net income (loss) before income tax $ (1,439) $ (2,337) $ (315) $ (207)  Net loss $ (1,439) $ (2,337) $ (315) $ (207)  Net loss per share - basic $ (0.03) $ (0.05) $ (0.01) $ (0.00)  Net loss per share - diluted $ (0.03) $ (0.05) $ (0.01) $ (0.00)  Weighted average number of shares outstanding - basic 45,161,273 48,817,940 49,173,773 49,316,852  Weighted average number of shares outstanding - diluted 45,161,273 48,817,940 49,173,773 49,316,852     Quarters Ended  March 31, June 30, September 30, December 31,  2018 2018 2018 2018  Revenues $ 6,867 $ 7,066 $ 6,867 $ 5,435  Gross profit $ 1,980 $ 106 $ 2,379 $ (471)  Net loss before income tax $ (2,081) $ (5,065) $ 63 $ (2,459)  Net loss $ (2,081) $ (5,065) $ 63 $ (2,459)  Net loss per share - basic $ (0.05) $ (0.11) $ 0.00 $ (0.05)  Net loss per share - diluted $ (0.05) $ (0.11) $ 0.00 $ (0.05)  Weighted average number of shares outstanding - basic 42,255,189 45,111,273 45,149,717 45,161,273  Weighted average number of shares outstanding - diluted 42,255,189 45,111,273 45,265,370 45,161,273 

Significant Accounting Polici_4

Significant Accounting Policies (Narrative) (Details)

1 Months Ended

3 Months Ended

12 Months Ended

Oct. 31, 2019

Dec. 31, 2019USD ($)item

Sep. 30, 2019USD ($)

Jun. 30, 2019USD ($)

Mar. 31, 2019USD ($)

Dec. 31, 2018USD ($)

Sep. 30, 2018USD ($)

Jun. 30, 2018USD ($)

Mar. 31, 2018USD ($)

Dec. 31, 2019USD ($)item

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Accounting Policies [Line Items]

Total intangible amortization expense

$ 32,000

$ 54,000

Standard product warranty period

1 year

Unbilled accounts receivable

$ 155,000

$ 224,000

$ 155,000

224,000

Advertising expense

0

0

Net loss

207,000

$ 315,000

$ 2,337,000

$ 1,439,000

2,459,000

$ (63,000)

$ 5,065,000

$ 2,081,000

4,298,000

9,542,000

Net cash used in operating activities

5,110,000

6,379,000

Cash and cash equivalents

3,515,000

3,359,000

3,515,000

3,359,000

$ 3,526,000

Net working capital

$ 8,800,000

$ 8,800,000

Work status reduction program, percentage decrease in senior management compensation

20.00%

Warrants [Member]

Accounting Policies [Line Items]

Expected term

5 years

5 years

Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]

Accounting Policies [Line Items]

Measurement input | item

0

0

Minimum [Member]

Accounting Policies [Line Items]

Accounts receivable, balance due

30 days

Minimum [Member] | Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]

Accounting Policies [Line Items]

Measurement input | item

0.0156

0.0156

Minimum [Member] | Warrants [Member] | Measurement Input, Price Volatility [Member]

Accounting Policies [Line Items]

Measurement input | item

0.403

0.403

Maximum [Member]

Accounting Policies [Line Items]

Accounts receivable, balance due

90 days

Maximum [Member] | Warrants [Member] | Measurement Input, Price Volatility [Member]

Accounting Policies [Line Items]

Measurement input | item

0.464

0.464

Equipment [Member]

Accounting Policies [Line Items]

Estimated useful life

3 years

Equipment [Member] | Maximum [Member]

Accounting Policies [Line Items]

Estimated useful life

10 years

Revolving Credit Facility [Member]

Accounting Policies [Line Items]

Outstanding debt

$ 2,891,000

$ 2,891,000

Remaining borrowing capacity

$ 1,200,000

$ 1,200,000

Significant Accounting Polici_5

Significant Accounting Policies (Summary of Activity Related to Warranty Liability Included in Other Current Liabilities) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Significant Accounting Policies [Abstract]
Beginning balance	$ 423	$ 468
Warranty accruals and adjustments	58	132
Warranty claims	(181)	(177)
Ending balance	$ 300	$ 423

Significant Accounting Polici_6

Significant Accounting Policies (Schedule of Potentially Dilutive Common Stock Equivalents) (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive common stock equivalents	32,246,091	21,279,526
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive common stock equivalents	5,404,985	4,678,420
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive common stock equivalents	19,295,773	9,055,773
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive common stock equivalents	7,545,333	7,545,333

Significant Accounting Polici_7

Significant Accounting Policies (Reconciliation of the Level 3 Warrant Liability Measured and Recorded at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Significant Accounting Policies [Abstract]
Balance as of January 1, 2019	$ 1,497
Fair value of warrants issuance during period
Change in fair value of warrant liability, net	(1,474)	$ (2,194)
Balance as of December 31, 2019	$ 23	$ 1,497

Significant Accounting Polici_8

Significant Accounting Policies (Impact of Adoption of ASC 842 on Balance Sheet) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease - right of use asset	$ 3,729	$ 4,267
Operating lease liabilities, current	775	964
Operating lease liabilities, non-current	3,067	3,432
Deferred rent	$ 277	129	$ 38
Adjustments Due to the Adoption of ASC 842 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease - right of use asset		4,267
Operating lease liabilities, current		964
Operating lease liabilities, non-current		$ 3,432

Impairment of Consumer Night _2

Impairment of Consumer Night Vision Business Assets (Narrative) (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2018USD ($)item	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)
Asset Impairment Charges [Line Items]
Number of products, exiting buisness associated with | item	2
Impairment of Consumer Night Vision Business inventory	$ 2,700	$ 1,270
Other accrued expenses		1,827	$ 1,401
Impairment of Consumer Night Vision Business tooling	100	$ 76
Contract Manufacturer [Member]
Asset Impairment Charges [Line Items]
Other accrued expenses	$ 1,400

Revenue Recognition (Narrative)

Revenue Recognition (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue Recognition [Abstract]
Accounts receivable, net	$ 3,966	$ 3,186
Revenue recognized related to contract liabilities	$ 200	$ 700

Revenue Recognition (Remaining

Revenue Recognition (Remaining Performance Obligations Narrative) (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-12-31 - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation	$ 1.4	$ 1.1
Remaining performance obligation, expected timing of satisfaction, period	12 months

Revenue Recognition (Schedule o

Revenue Recognition (Schedule of Disaggregated Revenue) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Revenues from contract with customer	$ 7,334	$ 7,919	$ 5,361	$ 6,112	$ 5,435	$ 6,867	$ 7,066	$ 6,867	$ 26,726	$ 26,235
North and South America [Member]
Disaggregation of Revenue [Line Items]
Revenues from contract with customer									14,566	13,969
Europe, Middle East, and Africa [Member]
Disaggregation of Revenue [Line Items]
Revenues from contract with customer									11,112	9,157
Asia Pacific [Member]
Disaggregation of Revenue [Line Items]
Revenues from contract with customer									$ 1,048	$ 3,109
Customer Concentration Risk [Member] | Revenues [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage									100.00%	100.00%
Customer Concentration Risk [Member] | Revenues [Member] | Military [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage									65.00%	75.00%
Customer Concentration Risk [Member] | Revenues [Member] | Commercial, including Industrial and Medical [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage									12.00%	10.00%
Customer Concentration Risk [Member] | Revenues [Member] | Consumer [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage									4.00%	6.00%
Customer Concentration Risk [Member] | Revenues [Member] | Multiple [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage									19.00%	9.00%

Revenue Recognition (Schedule_2

Revenue Recognition (Schedule of Contract Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Revenue Recognition [Abstract]
Unbilled Receivables (contract assets)	$ 155		$ 224
Deferred Revenue (contract liabilities)	$ (277)	$ (129)	$ (38)

Accounts Receivable, Net (Sched

Accounts Receivable, Net (Schedule of Accounts Receivable) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounts Receivable, Net [Abstract]
Accounts receivable	$ 4,105	$ 3,325
Less allowance for doubtful accounts	(139)	(139)
Accounts receivable, net	$ 3,966	$ 3,186

Inventories, Net (Schedule of C

Inventories, Net (Schedule of Components of Inventories) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Inventories, Net [Abstract]
Raw materials	$ 2,788	$ 3,701
Work in process	1,561	1,033
Finished goods	5,248	4,888
Total inventories	9,597	9,622
Less inventory reserve	(765)	(1,040)
Total inventories, net	$ 8,832	$ 8,582

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Schedule of Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Prepaid Expenses and Other Current Assets [Abstract]
Vendor prepayments	$ 657	$ 702
Other prepaid expenses	473	173
Total prepaid expenses and other current assets	$ 1,130	$ 875

Equipment, Furniture and Leas_3

Equipment, Furniture and Leasehold Improvements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total equipment, furniture and leasehold improvements	$ 21,278	$ 20,157
Less: accumulated depreciation	(13,178)	(11,236)
Equipment, furniture and leasehold improvements, net	8,100	8,921
Depreciation expense	1,900	1,900
Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Total equipment, furniture and leasehold improvements	893	800
Lab and Factory Equipment [Member]
Property, Plant and Equipment [Line Items]
Total equipment, furniture and leasehold improvements	17,482	17,107
Furniture, Fixtures and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Total equipment, furniture and leasehold improvements	59	48
Assets Under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Total equipment, furniture and leasehold improvements	116	66
Depreciation expense	11
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Total equipment, furniture and leasehold improvements	2,668	2,114
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total equipment, furniture and leasehold improvements	$ 60	$ 22

Debt _ Line of Credit (Narrativ

Debt / Line of Credit (Narrative) (Details) - USD ($)	Dec. 21, 2016	Dec. 31, 2019	Dec. 31, 2018
Line of Credit Facility [Line Items]
Interest paid, capitalized or accrued		$ 82,000	$ 82,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Borrowing capacity description		provides for up to a maximum amount of $5 million based on a borrowing base equivalent of 85% of eligible accounts receivable plus the lesser of $2 million or 50% of eligible inventory.
Maximum borrowing capacity	$ 5,000,000
Borrowing base equivalent of eligible accounts receivable, percentage	85.00%
Monthly interest payment	$ 2,000
Monthly administrative fee	$ 1,000
Annual facility fee on maximum amount borrowable	1.00%
Effective interest rate of funds borrowed		7.75%
Renewal date		Dec. 31, 2019
Automatic renewal date		Dec. 31, 2020
Line of credit facility term	3 years
Automatic renewal term		1 year
Debt issuance costs	$ 200,000
Minimum tangible net worth required for compliance	13,000,000
Minimum working capital required for compliance	$ 4,000,000
Remaining borrowing capacity		$ 1,200,000
Minimum [Member] | Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Minimum interest rate	6.50%
Maximum [Member] | Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Borrowing base equivalent of eligible inventory	$ 2,000,000
Borrowing base equivalent of eligible inventory, percentage	50.00%
Prime Rate [Member] | Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate	3.00%

Debt _ Line of Credit (Schedule

Debt / Line of Credit (Schedule of Line of Credit) (Details) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Line of Credit Facility [Line Items]
Revolving credit facility	$ 2,891
Less unamortized debt issuance costs
Revolving credit facility, net	$ 2,891

Leases (Narrative) (Details)

Leases (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	May 02, 2019
Lessee, Lease, Description [Line Items]
Finance lease, term of contract				3 years
Rent expense		$ 1	$ 1
Hopewell Junction, NY [Member]
Lessee, Lease, Description [Line Items]
Lease expiration date		May 31, 2024
Santa Clara, California [Member]
Lessee, Lease, Description [Line Items]
Lease extension term	2 years
Lease extension expiration date	Oct. 31, 2021

Leases (Components of Lease Exp

Leases (Components of Lease Expense) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Finance Lease Cost:
Amortization of right-of-use assets	$ 11
Interest on lease liabilities	3
Operating lease cost	986
Short-term lease cost	58
Total Lease Cost	$ 1,058

Leases (Schedule of Other Infor

Leases (Schedule of Other Information) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Leases [Abstract]
Operating cash flows from operating leases	$ 1,012
Financing cash flows from finance leases	13
Right-of-use assets obtained in exchange for new finance lease liabilities	50
Right-of-use assets obtained in exchange for new operating lease liabilities	110
Finance lease right-of-use assets	40
Operating lease right-of-use assets	3,729	$ 4,267
Finance lease liability, current	16
Finance lease liability, non-current	24
Operating lease liabilities, current	775	964
Operating lease liabilities, non-current	$ 3,067	$ 3,432
Weighted average remaining lease terms - finance leases	2 years 3 months 29 days
Weighted average remaining lease terms - operating leases	4 years 5 months 1 day
Weighted average discount rate - finance leases	10.91%
Weighted average discount rate - operating leases	8.48%

Leases (Future Annual Minimum L

Leases (Future Annual Minimum Lease Payments and Finance Lease Commitments) (Details) $ in Thousands	Dec. 31, 2019USD ($)
Operating Leases
2020	$ 1,063
2021	1,054
2022	1,014
2023	1,022
2024	426
Thereafter
Total undiscounted future minimum lease payments	4,579
Less imputed interest	737
Lease liability	3,842
Finance Leases
2020	20
2021	20
2022	6
2023
2024
Thereafter
Total undiscounted future minimum lease payments	46
Less imputed interest	6
Lease liability	$ 40

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Line Items]
U.S. Federal income tax benefit at federal statutory rate	21.00%	21.00%	35.00%
Reduction to deferred tax assest valuation allowance		$ 19,000,000
Expected refund for AMT credit carryforward	$ 200,000
Valuation allowance	34,978,000	34,726,000
Net operating loss carryforwards	142,674,000
Research and development tax credit carryforwards	2,479,000	2,438,000
Unrecognized tax benefits	0	0
Unrecognized tax benefits, interest and penalties	0	$ 0
Minimum [Member]
Income Tax Disclosure [Line Items]
U.S. Federal income tax benefit at federal statutory rate		21.00%
Expired [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	5,300,000
Indefinite [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 14,700,000

Income Taxes (Schedule of Net L

Income Taxes (Schedule of Net Loss Before Income Taxes) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Income Taxes [Abstract]
Domestic, current									$ (4,298)	$ (9,542)
Loss before provision for income taxes	$ (207)	$ (315)	$ (2,337)	$ (1,439)	$ (2,459)	$ 63	$ (5,065)	$ (2,081)	$ (4,298)	$ (9,542)

Income Taxes (Schedule of Defer

Income Taxes (Schedule of Deferred Taxes) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Income Taxes [Abstract]
Federal and state net operating loss carryforwards	$ 30,428	$ 30,350
Research and development tax credit carryforwards	2,479	2,438
Stock based compensation	1,632	1,470
Other provision and expenses not currently deductible	1,327	1,345
Total deferred tax assets	35,866	35,603
Depreciation and amortization	(693)	(726)
Prepaid expenses	(195)	(151)
Total deferred liabilities	(888)	(877)
Less valuation allowance	(34,978)	(34,726)
Net deferred tax asset

Income Taxes (Schedule of Feder

Income Taxes (Schedule of Federal Net Operating Losses and Tax Credit Carryforwards) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Net Operating Losses	$ 142,674
Research and Development Tax Credits	2,479	$ 2,438
2019-2020 [Member]
Operating Loss Carryforwards [Line Items]
Net Operating Losses	24,931
Research and Development Tax Credits	653
2021-2024 [Member]
Operating Loss Carryforwards [Line Items]
Net Operating Losses	41,283
2025-2037 [Member]
Operating Loss Carryforwards [Line Items]
Net Operating Losses	61,755
Research and Development Tax Credits	1,826
No Expiration [Member]
Operating Loss Carryforwards [Line Items]
Net Operating Losses	$ 14,705
Minimum [Member] | 2019-2020 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, expiration	Jan. 1, 2019
Minimum [Member] | 2021-2024 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, expiration	Jan. 1, 2021
Minimum [Member] | 2025-2037 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, expiration	Jan. 1, 2025
Maximum [Member] | 2019-2020 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, expiration	Dec. 31, 2020
Maximum [Member] | 2021-2024 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, expiration	Dec. 31, 2024
Maximum [Member] | 2025-2037 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, expiration	Dec. 31, 2037

Income Taxes (Schedule of Recon

Income Taxes (Schedule of Reconciliation of Effective Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
U.S. Federal income tax benefit at federal statutory rate	21.00%	21.00%	35.00%
Change in valuation allowance	(6.00%)	(21.00%)
Permanent differences	7.00%	(3.00%)
NOL Expiration - 1998	(26.00%)
Other, net	4.00%	3.00%
Effective tax rate

Warrants (Summary of Warrants I

Warrants (Summary of Warrants Issued and Warrants Outstanding) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Jan. 25, 2018
Class of Warrant or Right [Line Items]
Exercise Price		$ 1.55
2015 Warrant Issuance [Member]
Class of Warrant or Right [Line Items]
Issued	383,500
Outstanding	383,500
Exercise Price	$ 2.05
Expire	2021-06
2016 Warrant Issuance [Member]
Class of Warrant or Right [Line Items]
Issued	2,947,949
Outstanding	2,947,949
Exercise Price	$ 2.60
Expire	2023-02
2017 Warrant Issuance 1 [Member]
Class of Warrant or Right [Line Items]
Issued	100,000
Outstanding	100,000
Exercise Price	$ 2.25
Expire	2022-03
2017 Warrant Issuance 2 [Member]
Class of Warrant or Right [Line Items]
Issued	1,650,000
Outstanding	1,650,000
Exercise Price	$ 2.45
Expire	2022-11
2018 Warrant Issuance [Member]
Class of Warrant or Right [Line Items]
Issued	4,004,324
Outstanding	3,974,324
Exercise Price	$ 1.55
Expire	2023-07
2019 Warrant Issuance 1 [Member]
Class of Warrant or Right [Line Items]
Issued	240,000
Outstanding	240,000
Exercise Price	$ 0.55
Expire	2024-04
2019 Warrant Issuance 2 [Member]
Class of Warrant or Right [Line Items]
Issued	4,000,000
Outstanding	4,000,000
Exercise Price	$ 0.49
Expire	2024-10
2019 Warrant Issuance 2 [Member] | Immediately Exercisable Pre-Funded [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.01
2019 Warrant Issuance 3 [Member]
Class of Warrant or Right [Line Items]
Issued	6,000,000
Outstanding	6,000,000
Exercise Price	$ 0.78
Expire	2024-10

Warrants (Fair Value of Warrant

Warrants (Fair Value of Warrants) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Class of Warrant or Right [Line Items]
Fair Value at December 31,	$ 23	$ 1,497
Change in Fair Value of common stock warrant liability	1,474	2,194
2018 January and February Issuance [Member]
Class of Warrant or Right [Line Items]
Fair Value at December 31,	22	1,342
2017 May issuance [Member]
Class of Warrant or Right [Line Items]
Fair Value at December 31,	$ 1	$ 155

Shareholders' Equity (Narrative

Shareholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 11, 2019	Apr. 09, 2019	Jan. 25, 2018	Dec. 31, 2019	Dec. 31, 2018	Feb. 13, 2020	Nov. 22, 2019
Class of Stock [Line Items]
Common stock, price per share			$ 1.35
Proceeds from offering			$ 11,900	$ 3,476	$ 12,172
Number of shares of common stock called by warrants			3,922,842
Warrants exercise price per share			$ 1.55
Number of shares of common stock called by each warrant			0.4
Offering close date				Jan. 29, 2018
Public offering of common shares, net of offering costs, shares			9,807,105
Registered Direct Offering [Member]
Class of Stock [Line Items]
Shares issued		4,000,000
Common stock, price per share	$ 0.49	$ 0.50
Proceeds from offering	$ 2,000	$ 2,000
Number of shares of common stock called by warrants	4,000,000
Warrants exercise price per share	$ 0.01
Concurrent Private Placement [Member]
Class of Stock [Line Items]
Common stock, price per share			$ 1.35
Proceeds from offering			$ 300
Number of shares of common stock called by warrants			81,487
Offering close date				Feb. 15, 2018
Public offering of common shares, net of offering costs, shares			203,708
ATM Offering [Member]
Class of Stock [Line Items]
Number of shares of common stock called by warrants							5,000,000
Warrants issued, value							$ 1,700
Commission rate							3.00%
Unregistered [Member]
Class of Stock [Line Items]
Number of shares of common stock called by warrants		3,000,000
Unregistered [Member] | Registered Direct Offering [Member]
Class of Stock [Line Items]
Number of shares of common stock called by warrants	3,000,000
Warrants exercise price per share	$ 0.78	$ 0.78
Period after issuance in which warrants are exercisable	6 months	9 months
Warrant term	5 years 6 months	5 years 6 months
Subsequent Event [Member] | ATM Offering [Member]
Class of Stock [Line Items]
Warrants issued, value						$ 2,500
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares designated				10,000	10,000
Preferred stock, liquidation preference				$ 5,659	$ 5,659
Preferred stock, conversion price per share				$ 0.75
Preferred stock, redemption price per share				$ 1,000
Preferred stock, shares issued				5,659	5,659
Preferred stock, shares outstanding				5,659	5,659

Shareholders' Equity (Common Sh

Shareholders' Equity (Common Share Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Shareholders' Equity [Abstract]
Options exercised	12,500	99,937
Proceeds	$ 9	$ 98
Warrants exercised		30,000
Proceeds		$ 46

Stock Compensation (Narrative)

Stock Compensation (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options in-the-money	0
Closing stock price	$ 0.34
Unrecognized stock option compensation, net of forfeitures	$ 400,000
Unrecognized compensation cost, weighted average period of recognition	8 months 12 days
Weighted average fair value per share for options granted	$ 0.65	$ 1.70
Dividend yield	0.00%	0.00%
Intrinsic value of options exercised	$ 2,000
Dividend declared and paid	$ 0	$ 0
2005 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee purchase price, percentage of fair market value	85.00%
Shares available for issuance/grant			300,000
2017 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance/grant	49,834
Shares authorized		2,000,000
2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized	5,000,000
2019 Employee Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance/grant	5,000,000
2019 Consultant and Non-Employee Director Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance/grant	2,000,000
Share-based Payment Arrangement, Tranche One [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
Share-based Payment Arrangement, Tranche One [Member] | 2019 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year

Stock Compensation (Schedule of

Stock Compensation (Schedule of Option Activity) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Stock Compensation [Abstract]
Number of Shares, Outstanding at December 31, 2018	4,678,420
Number of Shares, Options granted	1,438,695
Number of Shares, Options exercised	(12,500)	(99,937)
Number of Shares, Options forfeited	(9,200)
Number of Shares, Options cancelled or expired	(690,430)
Number of Shares, Outstanding at December 31, 2019	5,404,985	4,678,420
Number of Shares, Vested or expected to vest at December 31, 2019	5,401,528
Number of Shares, Exercisable at December 31, 2019	5,232,179
Weighted Average Exercise Price, Outstanding at December 31, 2018	$ 2.81
Weighted Average Exercise Price, Options granted	0.65
Weighted Average Exercise Price, Options exercised	0.70
Weighted Average Exercise Price, Options forfeited	2.66
Weighted Average Exercise Price, Options cancelled or expired	1.54
Weighted Average Exercise Price, Outstanding at December 31, 2019	2.40	$ 2.81
Weighted Average Exercise Price, Vested or expected to vest at December 31, 2019	2.40
Weighted Average Exercise Price, Exercisable at December 31, 2019	$ 2.40
Weighted Average Remaining Contractual Life (In Years), Outstanding at December 31, 2019	3 years 6 months 7 days
Weighted Average Remaining Contractual Life (In Years), Vested or expected to vest at December 31, 2019	3 years 6 months 7 days
Weighted Average Remaining Contractual Life (In Years), Exercisable at December 31, 2019	3 years 6 months 7 days

Stock Compensation (Schedule _2

Stock Compensation (Schedule of Allocation of Non-Cash Stock-Based Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock compensation expense	$ 551	$ 610
Cost of Revenues [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock compensation expense	25	36
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock compensation expense	85	95
Selling, General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock compensation expense	$ 441	$ 479

Stock Compensation (Schedule _3

Stock Compensation (Schedule of Key Assumptions of Fair Value of Stock Options Granted) (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Risk free interest rates, minimum	1.77%	2.16%
Risk free interest rates, maximum	2.48%	2.75%
Expected volatility, minimum	41.70%	46.40%
Expected volatility, maximum	49.20%	50.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	3 years 6 months	3 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	4 years	4 years 9 months 18 days

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2018
Commitments and Contingencies [Abstract]
Equipment purchases commitments	$ 300,000
Demand letter for payment	$ 900,000
Consumer Night Vision, accrued invoices			$ 1,000,000
Fully vested service period	5 years
Percentage employer matches employee contributions	50.00%
Percentage employer matches to a maximum qualified compensation	3.00%
Employer contributions	$ 100,000	$ 0

Quarterly Financial Informati_3

Quarterly Financial Information (Schedule of Quarterly Financial Information) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Quarterly Financial Information [Abstract]
Revenues	$ 7,334	$ 7,919	$ 5,361	$ 6,112	$ 5,435	$ 6,867	$ 7,066	$ 6,867	$ 26,726	$ 26,235
Gross profit	2,676	2,491	225	1,336	(471)	2,379	106	1,980	6,728	3,994
Net (loss) income before income tax	(207)	(315)	(2,337)	(1,439)	(2,459)	63	(5,065)	(2,081)	(4,298)	(9,542)
Net income (loss)	$ (207)	$ (315)	$ (2,337)	$ (1,439)	$ (2,459)	$ 63	$ (5,065)	$ (2,081)	$ (4,298)	$ (9,542)
Net loss per share: Basic	$ 0	$ (0.01)	$ (0.05)	$ (0.03)	$ (0.05)	$ 0	$ (0.11)	$ (0.05)	$ (0.09)	$ (0.21)
Net loss per share: Diluted	$ 0	$ (0.01)	$ (0.05)	$ (0.03)	$ (0.05)	$ 0	$ (0.11)	$ (0.05)	$ (0.09)	$ (0.21)
Weighted average common shares outstanding - Basic	49,316,852	49,173,773	48,817,940	45,161,273	45,161,273	45,149,717	45,111,273	42,255,189	48,132,714	44,429,114
Weighted average number of shares outstanding - diluted	49,316,852	49,173,773	48,817,940	45,161,273	45,161,273	45,265,370	45,111,273	42,255,189	48,132,714	44,429,114
Change in fair value of common stock warrant liability									$ 1,474	$ 2,194

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - ATM Offering [Member] - USD ($) $ in Thousands	Feb. 13, 2020	Nov. 22, 2019
Warrants issued, value		$ 1,700
Subsequent Event [Member]
Warrants issued, value	$ 2,500
Accrued sales commission	$ 15